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ABSTRACT 
  
Diabetes leads to a variety of secondary complications. At the heart of these 
complications lies endothelial cells (ECs) – cells that take up unregulated plasma 
glucose, experience various biochemical alterations, and provide the basis for whole 
organ vascular dysfunctions.  With the purpose of generating new vascular networks for 
the treatment of these chronic complications, my initial work focused on vascular stem 
cells (VSCs). VSCs have the ability to differentiate into both endothelial (EPC) and 
mesenchymal (MPC) progenitor cells, both of which are necessary for the creation of 
stable and functional blood vessels. To establish whether these progenitor populations 
retain their integrity in diabetes, we investigated their cellular activity in a high glucose 
(HG) setting. Contrary to our expectations, EPCs evaded the negative effects of HG 
while MPCs displayed some functional alterations. Importantly, we noted MPCs in HG 
to be skewed towards the adipocyte lineage, while differentiation to both osteoblasts 
and chondrocytes was suppressed.  
 MPC alterations exposed in our study are reminiscent of phenotypic changes that 
occur in the bone marrow of long-term diabetic patients. To elucidate the mechanism 
behind this alteration in MPC differentiation we examined the Wnt signaling pathway in 
a comprehensive manner. The results of this study have revealed a novel finding. We 
have demonstrated the autogenous upregulation of non-canonical Wnt11 in HG-treated 
MPCs, that signals through the Wnt/Ca2+/protein kinase C (PKC) pathway to stimulate 
adipogenesis. Increase in adipocytes in human diabetic marrow samples correlated with 
a decrease in the number of stem cells. We have also shown that enhanced 
iii 
 
adipogenesis in marrow samples may disrupt the stem cell niche by altering 
Angiopoeitin/Tie signaling axis. Taken together, targeting the conversion of stem cells to 
adipocytes could be an effective means to combat many chronic diabetic complications. 
Preventing adipogenesis may restore stem cell numbers in diabetic patients enabling 
endogenous repair.  
 
 
Key words: diabetes, stem cell, vasculogenesis, hyperglycemia, progenitor cells, 
differentiation, adipocyte, Wnt signaling, stem cell niche   
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CHAPTER 1 – INTRODUCTIONa 
 
1.1 Chronic diabetic complications  
 
Diabetes is a chronic and debilitating metabolic disease that presently has no 
cure.  Currently, the total number of people with diabetes is upwards of 221 million and 
in North America alone, more than 10% of the population is affected1. This amounts to a 
staggering economic burden, estimated to be above $6 billion yearly in Canada2 and 
close to $245 billion in the United States3. Although the incidence in North America is 
quite alarming, close to 80% of diabetes-related deaths occur in low- and middle- 
income countries due to poor management of complications and lower standards of 
healthcare4. Despite great efforts to combat this disease, the World Health Organization 
projects that diabetes-related deaths will more than double by the year 20304.    
The most important discovery in the diabetes field was that of insulin in 1921. 
Exogenous insulin significantly alleviated diabetic coma and ketoacidosis, saving 
millions of lives. However, diabetic patients today still experience morbidity and mortality 
due to the chronic secondary complications that arise over time. These long-term 
complications manifest as micro- (retinopathy, neuropathy, nephropathy, and 
cardiomyopathy) and macro- (atherosclerosis) vascular dysfunctions5. Although the 
clinical features of the complications are quite varied, the underlying cause is an 
                                            
a
 Parts of this chapter have been published:  Keats EC, Khan ZA. Vascular stem cells in diabetic 
complications: evidence for a role in the pathogenesis and the therapeutic promise. Cardiovasc Diabetol. 
2012; 11:37. doi: 10.1186/1475-2840-11-37.  The BioMed Central applies the Creative Commons 
Attribution License (CC-BY Attribution 2.0) to works.  Under this license, authors retain ownership of the 
copyright for their content.  No permission is required from the publishers. 
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aberration in the vasculature of the target organ involved. Two major clinical trials paved 
the way to better understanding the cause of the diabetic complications: the Diabetes 
Control and Complications Trial (DCCT) and the United Kingdom Perspective Diabetes 
Study (UKPDS), completed in 1993 and 1997 respectively. In both trials, type 1 and 
type 2 diabetic patients were put under intensive glycemic control, and in both cases, 
there was delayed progression and/or inhibition of the onset of diabetic complications6,7. 
Other factors, such as hyperlipidemia and hyperinsulinemia, undoubtedly contribute to 
the pathogenesis of diabetic complications. However, clinical trial results and years of in 
vitro and in vivo research confirm the notion that hyperglycemia is the primary cause of 
micro- and macro-angiopathy seen in long-term diabetes.
 3 
1.2 Molecular basis of the vascular dysfunction in diabetic complications
 
Endothelial cells (ECs) are a critical component of the vascular unit. These 
specialized cells form the inner lining of blood vessels, sit on a basement membrane, 
and are surrounded by supportive perivascular cells (pericytes or smooth muscle cells) 
(figure 1.1). ECs not only function as a barrier – producing an interface between 
circulating blood and the perfused tissue – but also play a prominent role in tissue 
functioning as well as organogenesis. These cells are involved in important vascular 
processes such as regulating blood flow and pressure, permeability, blood fluidity, the 
thrombotic/fibrinolytic balance, and leukocyte traffic8,9.  
Due to their anatomical location in the blood vessel, ECs are not surprisingly the 
first to encounter circulating plasma glucose. Glucose transporters (Gluts) facilitate the 
uptake of glucose10-12. The predominant Glut in the vascular ECs is Glut113,14. Although 
Gluts are typically expressed in a tissue-specific manner, Glut1 is ubiquitously 
expressed under normal growth conditions15.  Unlike other glucose transporters, Glut1 
activity and expression level does not change with altered plasma glucose levels. This 
indicates that hyperglycemia may have profound detrimental effects on vascular ECs 
specifically, as glucose uptake is not actively regulated13,14. There are certain 
conditions, however, that may alter Glut1 expression. For example, hypoxia increases 
Glut1 levels in ECs16. This additive effect of hyperglycemia and hypoxia may be one 
mechanism behind the uncontrollable dysfunction of vascular ECs in diabetic 
complications.    
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Figure 1.1: Schematic of large and small blood vessels. Large vessels contain a 
prominent elastic tissue and multiple layers of the contractile cells (smooth muscle 
cells). Small capillaries may or may not have contractile cell (pericyte) coverage. 
Endothelial cells in capillaries sit on a thin basement membrane. 
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In vitro studies have shown that exposure to high levels of glucose lead to 
biochemical alterations in mature vascular ECs17. These alterations manifest as 
increased production of extracellular matrix proteins, such as collagen and fibronectin, 
increased production of the procoagulant protein von Willebrand Factor (vWF), and 
altered cellular activities18-20. In addition to a reduction in proliferation and migration21, a 
number of studies have provided evidence that hyperglycemia can directly promote EC 
apoptosis22-24. This apoptotic pathway is believed to be activated by increased oxidative 
stress, increased intracellular Ca2+, mitochondrial dysfunction, changes in intracellular 
fatty acid metabolism, activation of mitogen activated protein kinase (MAPK) signaling 
pathways, and impaired phosphorylation/activation of protein kinase B (also known as 
Akt)25,26.  
One of the earliest functional changes, which precedes any structural change in 
the vasculature of the target organs, is the impairment of endothelial-dependent 
vasodilation19. This impairment arises because of two inter-regulated mechanisms: 
decreased production of vasodilators and increased production of vasoconstrictors. 
Diminished levels of nitric oxide (NO) and increases in endothelin-1 (ET-1), the most 
potent endogenous vasoconstrictor, have been demonstrated in vascular ECs cultured 
in high glucose19. We, and others, have shown that the enzymes involved in NO 
production are up-regulated in ECs upon glucose challenge27. However, uncoupling of 
the enzymatic reaction and possible sequestration of NO by oxidative stress leads to 
significantly reduced NO19,28.  Another well-established pathway leading to increased 
EC damage in diabetes is the oxidative stress pathway. Hyperglycemia produces 
reactive oxygen species (ROS) in ECs, such as hydroxyl radicals, superoxide anions, 
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and hydrogen peroxide18 . The overproduction of ROS may also be attributed to the 
activation of alternate metabolic/signaling pathways such as the polyol pathway and 
hexoseamine pathway, and signaling through protein kinase C (PKC), advanced 
glycation end-product (AGE) formation, and Poly (ADP-ribose) polymerase (PARP) 
activation17,28,29 (figure 1.2). Each of these pathways may potentiate each other, 
culminating in increased ET-1 activity, reduced NO bioavailability, oxidative stress, and 
EC dysfunction. Remarkably, the biochemical changes that we see in high glucose-
treated ECs are reminiscent of the chronic complications that present in diabetic 
patients. 
We now know that altered ECs provide a backbone for the long-term vascular 
dysfunctions that arise in diabetic patients (figure 1.3). Changes in the structure and 
function of ECs leads to subsequent aberration of entire vascular networks, and tissues 
will begin to shows signs of poor blood flow and ischemia30. Normally, an adaptive 
response would be expected under these conditions. While there is a vascular response 
in diabetic patients, it is not uniform and varies depending on the organ system 
involved. The retina and kidneys typically exhibit enhanced blood vessel formation, 
while this process is impaired in the heart and lower limbs30,31. The selectivity in the 
target organ system in diabetes suggests the importance of both the tissue 
microenvironment and the intrinsic properties of the ECs19. 
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Figure 1.2: Mechanisms of glucose-induced oxidative stress in ECs. 
Hyperglycemia leads to cell death by the overproduction of ROS and impairment in the 
ROS neutralizing enzymes. Multiple pathways may lead to ROS production. A 
consequence of activating these oxidant pathways is the depletion of co-factors 
required by the anti-oxidant enzyme systems. The net effect is an imbalance in ROS 
production and ROS clearance [AGE=advanced glycation end product; 
ATP=adenosine-5'-triphosphate; iNOS=inducible nitric oxide synthase; LOX-1=receptor 
for oxidized-low density lipoprotein; NAD=nicotinamide adenine dinucleotide; 
NADPH=reduced NAD phosphate; ox-LDL=oxidized-low density lipoprotein; PARP=poly 
(ADP-ribose) polymerase; RAGE=receptor for AGE]. 
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Figure 1.3: Mechanisms leading to vascular disruption in diabetes. High glucose 
causes various biochemical and molecular changes in the vascular ECs, resulting in 
functional and structural alterations of the target organ vascular bed. Impaired 
vasoregulation and loss of vessel integrity leads to reduced blood flow and ischemia. In 
response, the target organ exhibits neovascularization (diabetic 
retinopathy/nephropathy) or fibrosis (diabetic cardiomyopathy/neuropathy) 
[AGE=advanced glycation end product; BM=basement membrane; EC=endothelial cell; 
ECM=extracellular matrix; EDV=endothelial-dependent vasodilation; ET-1=endothelin-1; 
MAPK=mitogen-activated protein kinase; PKB=protein kinase B; PKC=protein kinase 
C].  
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Growth factors and extracellular matrix (ECM) proteins are two major regulators  
of the balance that exists between neovascularization and scar formation/fibrosis in 
diabetic complications. Vascular endothelial growth factor (VEGF) is an EC-specific 
mitogen that promotes angiogenesis in a number of disease models. In parallel with a 
lack of angiogenesis that occurs in the heart in diabetes, a reduced expression of VEGF 
and its receptors is reported in the myocardium32. This is in direct contrast to elevated 
VEGF levels in the retina33, correlating with uncontrolled retinal neovascularization. In 
addition to growth factors, the ECM regulates the vascular cells and may contribute to 
the differential effects of hyperglycemia in diabetic complications. In a normal setting, 
binding of EC surface integrins to the ECM proteins regulates cell survival/apoptosis, 
growth, and cytoskeletal changes34. Therefore, angiogenesis is highly dependent on the 
interactions between the cellular components of the vascular unit and the surrounding 
scaffolding proteins. In fact, ECM changes that are believed to promote 
neovascularization during tumorigenesis are mimicked in retinal vascular development, 
and include increases in fibronectin and laminin35. Retinal basement membranes of 
diabetic animals show a similar protein profile- with elevated collagen IV, laminin and 
fibronectin as early as 8 weeks following the onset of diabetes36. Along with ECM 
protein heterogeneity, increased ECM deposition in the heart may contribute to the 
impaired angiogenic response. Cardiac fibroblasts, which are present in significant 
numbers, may be responsible for this unregulated deposition of ECM proteins through 
the action ET-1, which has been shown in vitro to increase production of ECM 
components by fibroblasts37,38.  
10 
 
Regardless of the organ system involved, vascular ECs are the primary 
mediators of hyperglycemic damage and they undergo significant structural and 
functional alterations. Subsequently, impaired vasoregulation, increased permeability, 
ECM expansion, and dysfunction of entire vascular networks causes reduced blood flow 
to the target organ, setting the stage for uncontrolled advancement of complications. To 
stop the progression and repair the hyperglycemic damage, altered ECs would need to 
be replaced or, alternatively, brand new vascular networks created.  Considering 
mounting evidence of stem/progenitor cells in various tissues including the blood vessel 
wall39, one can speculate that these stem/progenitor cells are also affected and lead to 
an impaired repair mechanism in diabetes.  
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1.2 Vascular stem cells (VSCs): current evidence and promise  
 
Stem cells are defined by their ability to both self-renew and differentiate into 
functionally mature cells40. The potential of the cells is determined by the hierarchy and 
specialization level, with embryonic stem cells being the most versatile. Stem cells have 
been identified in a variety of post-embryonic tissues, including bone marrow, blood, fat, 
and skin41,42. Discovering these stem cell populations has presented the opportunity for 
non-invasive tissue repair and tissue regeneration, including the vascular tissue. 
However, to generate new vascular networks (de novo formation), a suitable cell source 
must first be identified. Ideally, it would be one cell type or subpopulation that could 
produce both the endothelial and supportive perivascular cells that make up the 
vascular unit. The notion of a specific vascular stem cell (VSC) able to produce 
mature/functional cells of the blood vessel wall is slowing gaining momentum. Several 
groups have demonstrated the existence of a common vascular precursor cell in both 
mouse and human studies. Kattman et al. used cell tracing studies in mice and showed 
that cardiomyocytes arise from a cell population expressing the VEGF receptor-2 
(VEGFR2/Flk1)43, indicating that they develop from a progenitor that also has vascular 
potential. They followed up these studies with an embryonic stem cell differentiation 
model, in which they isolated cardiovascular progenitors (brachyury+; VEGFR2+) from 
human embryoid bodies (EBs) and successfully demonstrated their potential for 
generating cardiomyocytes, endothelial cells, and vascular smooth muscle cells43. 
Yamashita and colleagues showed that VEGFR2+ cells, derived from embryonic stem 
cells, could differentiate into both endothelial and mural cells through differing culture 
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conditions44. These cells were also able to reproduce the vascular organization process 
when placed in three-dimensional culture systems44. Similarly, Ferreira et al. 
demonstrated that vascular progenitors (CD34+) isolated from EBs will give rise to 
endothelial and smooth muscle-like cells, and have the ability to form vascular networks 
when implanted in vivo45.  
Although the exact identity of the VSC is not yet unanimous, there is evidence 
that this cell type is found in the bone marrow and circulation and is functionally distinct 
from hematopoietic stem cells (HSCs). Selection of CD133+ cells from the circulation 
purifies a population(s) of cells that under different culture conditions will produce 
lineage-restricted endothelial progenitor cells (EPCs) and mesenchymal/mesodermal 
progenitor cells (MPCs)40,46-49. However, cells expressing pan hematopoietic marker 
CD45 fail to yield endothelial cells50-52. It is unknown thus far whether one or more stem 
cell subtypes reside within this CD133+ population that are limited in their capacity to 
produce endothelial and mesenchymal cell types. Importantly, CD133+ stem cell-
derived EPCs and MPCs form functional vascular networks44,45,51. Whether this is a 
feasible avenue for diabetic patients is just recently being probed. 
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1.3  Endothelial progenitor cells (EPCs) and diabetic complications 
 
Progenitor, or precursor, cells are committed (lineage-restricted) and highly 
proliferative derivatives of stem cells. These cells may be capable of doubling their 
population every 10-15 hours53. Unlike fully mature cells, progenitors express markers 
of full maturity in addition to select stem cell markers53. For example, EPCs share 
markers of both stem and mature endothelial lineages54. With the potential use of EPCs, 
either clinically or as a biomarker, accurate identification and reproducible classification 
is of great importance. Despite advances in research on this subject, a lack of 
consensus remains on how EPCs should be defined. Traditionally, EPCs have been 
identified as the spindle-shaped or polymorphic cells that appear within 2-4 days in 
culture after isolation of the mononuclear cell (MNC) fraction from blood or bone 
marrow55(figure 1.4). These cells are characterized by Ulex europaeus agglutinin 
binding and DiI-labeled acetylated-low density lipoprotein (LDL) uptake56-58, two 
properties that are typically considered functional characteristics of ECs. However, 
along with expressing some EC markers, these ‘short-term’ EPC colonies also express 
monocyte-specific marker CD14 and/or hematopoietic cell marker CD45. Further, 
acetylated-LDL uptake was identified in 1979 as a known feature of monocytes59. Ulex 
europaeus agglutinin is a lectin which binds to the EC surface via fucose resides. These 
fucose residues are not specific to the ECs60. Taken together, these early outgrowth 
colonies encompass a variety of cell types, making EPC identification challenging.  
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Figure 1.4: Early and late EPCs. Schematic illustrating the two major types of cell 
colonies arising from blood and bone marrow mononuclear cells. Short term colonies 
appear within 7days of culture and are comprised of spindle shape or polymorphic cells. 
These early EPCs (also called angiogenic EPCs) express a number of endothelial and 
hematopoietic markers but fail to proliferate in culture. Late colonies, appearing from 7 – 
21 days, are comprised of epitheliod cells with high proliferative capacity. These late 
EPCs (also called vasculogenic EPCs) express all markers of mature endothelial cells 
but lack hematopoietic marker expression. 
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How then do we define EPCs? The single most important property (or functional 
attribute) of late outgrowth EPCs is their ability to incorporate into blood vessels. In 
other words, they participate in vasculogenesis61,62.  In comparison, early EPCs are 
considered angiogenic because they facilitate angiogenesis through the elaboration of 
growth factors. We, and others, have extensively characterized marker expression and 
cellular activities of vasculogenic EPCs. EPCs display properties of both mature ECs 
and unipotent progenitor cells. However, EPCs differ from mature ECs in CD133 
expression (positive on EPCs but readily lost upon culture)47,63, proliferation/growth 
kinetics (EPCs show lower population doubling time and higher cumulative population 
doublings)50,64, and response to endostatin (EPCs are stimulated whereas mature ECs 
are inhibited)47. Over time, EPCs resemble mature ECs in terms of marker expression 
and all cellular activities47,50,51. Much of the controversy behind angiogenic and 
vasculogenic EPCs could be negated by performing functional cellular activity tests 
(summarized in figure 1.5). These include assessing the expression of endothelial-
specific markers47,50,51, activation by cytokine challenge47, and most importantly, the 
ability of the cells to create blood vessels50,51. 
EPCs may be involved in vascular dysfunction in chronic diabetic complications. 
It has been demonstrated that type 1 and type 2 diabetics maintain a lower circulating 
number of EPCs when compared with healthy subjects54,65-67. In two similar studies, 
flow cytometric analysis was used to quantify EPCs (CD34+/VEGFR2+/CD31+) in 
diabetic patients. These studies showed that EPCs were reduced by 44% and 40%, 
respectively65,68. More recently, the number of circulating CD34+/VEGFR2+ cells was 
shown to correlate with glycemic control in type 2 diabetic patients69. This study also 
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Figure 1.5: Characterization scheme for EPCs and MPCs. (A) EPCs express CD31 
and VE-cadherin, localized to the cell membrane, and vWF in the Wieble Palade 
bodies. VEGF is a mitogen for ECs and EPCs. Also, EPCs induce adhesion molecules 
when challenged with cytokines, similar to mature ECs. The progenitor properties 
include clonal growth potential and in vivo vasculogenesis. (B) MPCs express CD90, α-
SMA, and calponin. Upon treatment with PDGF and EGF, MPCs proliferate and also 
exhibit chemotaxis. The progenitor phenotype involves the ability of the cells to give rise 
to adipocytes, osteocytes, and chondrocytes [VEGF-A = vascular endothelial growth 
factor-A; TNF-α = tumor necrosis factor-α; PECAM = platelet endothelial cell adhesion 
molecule; VE-cadherin = vascular endothelial-cadherin; Mel-CAM = melanoma cell 
adhesion molecule; KDR = kinase insert domain receptor (VEGFR2); bFGF = basic 
fibroblast growth factor; EGF = epidermal growth factor; PDGF = platelet-derived growth 
factor; myosin HC = myosin-heavy chain; αSMA = α-smooth muscle actin].  
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highlighted the negative relationship between circulating CD34+/VEGFR2+ cells and 
arterial stiffness in diabetic patients. However, because these surface markers are not 
exclusive to EPCs, the reduced number may be inclusive of altered levels of 
hematopoietic stem/progenitor cells. In fact, a fairly large analysis of 120 patients with 
ischemic heart disease showed reduced levels of bone marrow-derived CD34+/CD45+ 
cells, which also correlated with glycated hemoglobin HbA1c levels70. In vitro 
experimental studies using early EPCs have also shown a lower angiogenic ability65 and 
impaired adherence to the mature EC monolayer in diabetes71,72. Less work has been 
done on the late vasculogenic EPCs, which display different cellular properties, and 
may respond quite differently than early EPCs to the adverse effects of high glucose.    
Despite the notion that EPC number may be reduced in long-term diabetes, there 
is still promise for their therapeutic potential. If the cellular activity is able to remain 
intact in a diabetic setting, administration of ex vivo expanded EPCs to a diabetic patient 
should essentially work to improve vascular dysfunction. Not only has successful 
expansion of adult blood-derived EPCs been shown in vitro, but their ability to form fully 
functional vascular networks has also been demonstrated in vivo46,50. It is important to 
note that in order to form stable and durable networks, EPCs require co-implantation 
with a source of perivascular cell. Mesenchymal progenitor cells (MPCs), also derived 
from the CD133+ stem cell fraction, may be a suitable candidate for this task. 
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1.4  Mesenchymal progenitor cells (MPCs) and diabetic complications 
 
MPCs are multipotent cells that are derived, along with EPCs, from the CD133+ 
population of circulating cells. MPCs can be isolated in large quantities from adult 
human bone marrow73. In addition, they have been identified in liver74, spleen74, and 
adipose tissue75. Like EPCs and other progenitor cell types, MPCs share properties of 
both stem and mature cells. They can be characterized by a combination of phenotypic 
and functional properties, including expression of cell surface markers, cell adhesion 
molecules, and differentiation potential (figure 1.5). Because there is not one marker 
that is specific to MPCs, all parameters must be taken into consideration when properly 
identifying this cell population. Mesenchymal cells in culture typically exude a spindle-
like morphology, however, some heterogeneity has been noted depending on the tissue 
source and especially when arising from differing species. MPCs are negative for both 
the endothelial marker CD31 and the hematopoietic marker CD4551. Analysis of mRNA 
and/or protein can be used to demonstrate expression of α-smooth muscle actin (α-
SMA), calponin, CD90, PDGFRβ, and NG246,51. Functionally, MPCs differentiate into the 
mesenchymal lineage cells including adipocytes, osteoblasts, and chondrocytes46,51,73.   
Not much is known about a possible pathogenic role of MPCs in diabetic 
complications. In terms of therapeutic benefit, however, recent studies show 
improvement and amelioration of complications, including cardiomyopathy, 
nephropathy, neuropathy, and wound healing by MPCs. Using a rat model of diabetic 
cardiomyopathy, MPCs were administered intravenously and shown to attenuate 
cardiac remodeling and improve myocardial function through a marked increase in the 
19 
 
activity of matrix metalloproteinase (MMP)-2 and decrease in MMP-976. In addition, 
reduced levels of VEGF, insulin-like growth factor-1 (IGF-1), adrenomedullin (AM), and 
hepatocyte growth factor (HGF) were found76. The MPCs differentiated into both 
cardiomyocytes and vascular ECs, improving myocardial perfusion and regeneration in 
the diabetic heart76. MPCs have also successfully improved diabetic nephropathy in 
mice. After systemic injection, the precursor cells were shown to engraft in the damaged 
kidneys and differentiate into renal cells, improving renal function and the regeneration 
of glomerular structures77,78. Furthermore, when injected intramuscularly, MPCs 
improve diabetic polyneuropathy through increased secretion of angiogenic cytokines 
such as basic fibroblast growth factor (FGF) and VEGF79. Lastly, in a model of skin 
wound healing, administration of MPCs in streptozotocin-induced diabetic rats 
completely normalized the delayed wound closure time80. This effect was mediated, in 
part, through a reduced number of infiltrating CD45+ cells into the wounds. This study 
involved ‘normal’ MPCs (i.e. cells isolated from non-diabetic rats), and the question 
remains whether diabetes causes alteration of the functional properties of MPCs. 
Although this is still an emerging field, a recent study showed that AGEs may increase 
the generation of reactive oxygen species and reduce the proliferation and migration of 
MPCs81. Whether this plays a role in human diabetes or in animal models of diabetic 
complications require further studies.   
Given the promising results of the animal studies and the advantages that MPCs 
have over other cell types (differentiation potential and capability for regulation of the 
immune response), they are likely to be good therapeutic candidates in diabetic 
complications. Several studies have also reported that treatment with MPCs can 
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enhance angiogenesis through paracrine effects82-84. This paracrine role may be 
important for the restructuring of vascular networks by providing angiogenic factors to 
facilitate EPC homing. 
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1.5  Therapeutic neovascularization in diabetes  
 
As diabetes is beginning to reach epidemic proportions, more efforts must be 
focused on combatting the vascular dysfunctions that inevitably arise in these patients. 
Experimental evidence shows that stem/progenitor cells isolated from diabetic mice are 
able to restore vascular homeostasis85,86. If function remains intact, a reduction in stem 
cell number is the likely deficit in diabetes. This reduction may take place anywhere 
between the bone marrow and the circulation, and could be caused by a number of 
factors such as impaired bone marrow release, loss of migratory ability, loss of 
differentiation potential, or shortened survival time in the peripheral circulation. 
However, if we can find a way to utilize our EPC and MPC populations to repair 
vascular damage and restore blood vessel functioning, there is hope that the chronic 
complications can be attenuated (figure 1.6). 
The success of therapeutic vascularization will rely on many factors, one of which 
being the ability of engineered blood vessels to form stable and functional anastomoses 
with the host vasculature. Neovascularization has been successfully shown thus far 
using human umbilical vein endothelial cells (HUVECs), as well as human 
microvascular endothelial cells (HDMECs)51,87,88. However, there are limitations to the 
clinical use of these particular EC types because of the lower yield. Considering the 
ease with which CD133+ VSCs can be isolated from adult peripheral blood and bone 
marrow, an opportunity is presented to obtain these cells non-invasively and in large 
enough quantities for differentiation and expansion ex vivo. Following expansion, the  
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Figure 1.6: The potential of VSCs for therapeutic use in diabetics. A schematic of 
our working hypothesis showing that CD133+ VSCs are non-invasively isolated from 
diabetic patients and differentiated into endothelial and mesenchymal lineages by 
defined media. EPCs and MPCs are then expanded ex vivo and re-implanted in the 
patients to repair the damage and restore vascular homeostasis [middle box shows the 
immunophenotype of VSCs; VEGF=vascular endothelial growth factor (obligatory factor 
for endothelial lineage)]. 
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cells can be implanted back into the diabetic patient to restore vascular homeostasis. It 
has previously been shown that adult and cord blood-derived EPCs can be expanded 
ex vivo and have the ability to form functional vascular networks in vivo50,89. Importantly, 
this requires co-implantation with a perivascular or mural cell source in order to maintain 
stable, functional networks. MPCs are an ideal candidate because, like EPCs, they can 
be isolated with ease from sites such as bone marrow73 and even adult blood90. We 
have previously shown the success of subcutaneous co-implantation of EPCs and 
MPCs into the backs of athymic nu/nu mice, resulting in the creation of human 
microvessels that formed functional anastomoses with the host vasculature51. Although 
we know VSCs may provide the basis for vasculogenesis in a nude mouse model, 
whether they are able to restore vascular homeostasis in an in vivo diabetic setting 
remains to be determined. The next important step is to directly examine the effects of 
high glucose on both progenitor cell populations.    
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1.6 Thesis overview  
 
This thesis demonstrates the natural progression of a scientific question. We have 
previously shown the success of neovascularization in a mouse model51. It then 
remained to be determined if this process is affected in diabetes, and whether VSCs are 
an appropriate source of EPCs and MPCs for the creation of new vascular networks.  
In Chapter 2, I set out to characterize EPCs and MPCs in a high glucose setting. My 
first aim was to derive both progenitor cell populations. My second aim was to examine 
the functional characteristics of EPCs and MPCs in a high glucose setting. My studies 
consisted of the following:  
 
1. Isolation of VSCs that have the required regenerative potential for therapeutic 
use in diabetic patients 
2. Perform directed differentiation of VSCs to the endothelial and mesenchymal 
lineages  
3. Investigate the effect of high glucose on the cellular activity of EPCs and MPCs  
 
The results of these studies provided novel insight into MPC dysfunction in diabetes, 
highlighting their selective differentiation to the adipocyte lineage. Not only does this 
alteration reflect the bone phenotype of long-term diabetics, but it hints at an intriguing 
connection between diabetes and obesity.  
In chapter 3, I reviewed potential mechanisms that may regulate adipogenesis – 
setting the stage for my experimental studies in chapter 4. My first aim was to establish 
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the alterations that occurred at each level of regulation of Wingless-type MMTV 
integration site members (Wnt) signaling with the addition of high glucose. My second 
aim was to manipulate each pathway using both genetic and chemical approaches in an 
attempt to prevent the high glucose-induced increase in adipogenesis. My final aim was 
to corroborate these results with in vivo data using both human and rat bone marrow 
specimens in order to establish the relationship of MPC differentiation to the stem cell 
niche. My studies consisted of the following:  
 
1. Elucidate the high glucose-induced changes in Wnt signaling during 
adipogenesis. 
2. Establish the precise role of β-catenin in the differentiation of MPCs to    
adipocytes. 
3. Determine the involvement of non-canonical Wnt signaling in the skewing of 
MPC differentiation. 
4. Examine alterations in the diabetic bone marrow stem cell niche. 
 
Taken together, these studies highlight novel findings regarding stem/progenitor cell 
function in a diabetic setting. The knowledge gained from this work will have far 
reaching consequences should it be expanded and exploited for clinical use.    
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CHAPTER 2 – UNIQUE RESPONSES OF STEM CELL-DERIVED VASCULAR 
ENDOTHELIAL AND MESENCHYMAL CELLS TO HIGH LEVELS OF GLUCOSEb 
 
 
This study focused on the characterization of EPCs and MPCs in a high glucose 
setting in order to establish their therapeutic potential for diabetic neovascularization. 
My first aim was to derive both progenitor cell populations. My second aim was to 
examine the functional characteristics of EPCs and MPCs in a high glucose setting. My 
studies consisted of the following:  
 
1. Isolation of adult human blood-derived VSCs that have the required regenerative 
potential for therapeutic use in diabetic patients. 
2. Perform directed differentiation of VSCs to the endothelial and mesenchymal 
lineages.  
3. Investigate the effects of high glucose on the cellular activity of EPCs and MPCs.
                                            
b
 Parts of this chapter have been published:  Keats E, Khan ZA. Unique responses of stem cell-derived 
vascular endothelial and mesenchymal cells to high levels of glucose. PLoS One. 2012;7(6):e38752. doi: 
10.1371/journal.pone.0038752. The Public Library of Science (PLOS) applies the Creative Commons 
Attribution License (CC-BY Attribution 3.0) to works.  Under this license, authors retain ownership of the 
copyright for their content.  No permission is required from the publishers. 
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2.1 Introduction  
 
The idea of a specific VSC population is one that is steadily gaining recognition. 
VSCs are a sub-population of CD133+ cells that are able to differentiate into mature 
cells of the vascular wall1,2. They are predominantly housed in the bone marrow, but 
can also be derived from the MNC layer of peripheral blood, making them an easily 
attainable source of cells. The existence of a common vascular stem/progenitor cell that 
can be derived from adult human blood samples highlights the feasibility of therapeutic 
vasculogenesis for long-term diabetic patients. Although we know VSCs may provide 
the basis for vasculogenesis in a nude mouse model3, whether they are able to restore 
vascular homeostasis in an in vivo diabetic setting remains to be determined. The 
effects of high glucose on the functionality of both EPCs and MPCs must be elucidated 
firstly. To date, the role of MPCs in diabetic complications has not been investigated, 
and much of the work done on EPCs (short-term colonies; 2-4 days in culture) is 
confounded by the presence of hematopoietic/monocytic cells within the studies4,5. 
These ‘early’ cells are characterized by Ulex europaeus agglutinin binding and DiI-
labeled acetylated-low density lipoprotein (LDL) uptake4,6,7. Both of these assays are 
not specific to ECs8,9. Therefore, a combination of both phenotypic and functional 
properties must be used to unambiguously identify both EPCs and MPCs so as not to 
impair the results of the studies. We herein determine the precise role of vascular 
endothelial and mesenchymal progenitor cells in a high glucose setting to highlight their 
potential application in diabetes therapy.  
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2.2 Materials and methods
All experiments were approved by the Research Ethics Board at the University of 
Western Ontario, London Ontario. 
 
2.2.1 Isolation, culture, and differentiation of VSCs  
 
Normal adult peripheral blood (US Biological, Salem, MA; age 26.16±6.79 yrs; 
n=9) and fresh bone marrow samples (Lonza Inc., Walkersville, MD; n=6) were obtained 
and mononuclear cell fraction was prepared by the Ficoll-Pacque centrifugation 
method10. To obtain adult blood EPCs (abEPCs), cell suspensions were cultured on 
fibronectin (FN; 1 μg/cm2; Millipore, Temecula, CA)-coated plates in modified 
endothelial cell media: complete Endothelial Basal Media-2 (EBM-2, Lonza Inc.) 
supplemented with 35% fetal bovine serum (FBS; Lonza Inc.), 1X PSF (antibiotic-
antimycotic solution; CellGro Mediatech Inc., Manassas, VA) and SingleQuots (Lonza 
Inc.; contains human epidermal growth factor, vascular endothelial growth factor, 
human basic fibroblast growth factor, insulin-like growth factor, hydrocortisone, heparin, 
ascorbic acid, and gentamicin/amphotericin B). The media was changed every day until 
colonies began to appear. Thereafter, the media was changed every other day. All 
subcultures were then performed with EBM2/20% FBS/SingleQuots/PSF media. Bone 
marrow samples were cultured on FN-coated plates in DMEM (Life Technologies, 
Burlington, ON) media, supplemented with 20% FBS, 1X PSF and no additional growth 
factors to yield MPCs. To assess the effect of high levels of glucose on abEPC and 
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bone marrow MPC (bmMPC) differentiation, the media was supplemented with 25 
mmol/L glucose from the initial plating. All other experiments were conducted on 
passage 2–6 cells with 3 technical and 3–5 biological replicates.  
 
Normal human dermal microvascular endothelial cells (HDMECs; CC-2516, 
Lonza Inc.) and human cord blood-derived EPCs (cbEPCs; derived from cord blood 
using the same protocol as mentioned above for adult blood; 2C-150A; Lonza Inc.) were 
used as control for the abEPCs. Human umbilical artery smooth muscle cells (uaSMCs; 
CC-2579; Lonza Inc.) were used as control for the bmMPCs. 
 
2.2.2 Cell staining 
 
Cultured cells were trypsinized and plated (10,000 cells/cm2) on FN-coated 8-
chambered slides one day prior to staining to allow for attachment of cells. 
Immunofluorescence staining for endothelial and mesenchymal cell markers was 
carried out by incubating the cells with primary antibodies at optimal concentrations 
(Table 1.1) for 1 hour at room temperature. Following primary incubation, a FITC- or 
Alexa488-conjugated secondary antibody was applied to the cells for 1 hour at room 
temperature. Slides were subjected to a nuclei counterstain using DAPI (Vector 
Laboratories, Burlington, ON) and mounted using Fluoromount (Sigma-Aldrich, Oakville, 
ON) mounting medium. Images were taken using Olympus BX-51 fluorescent 
microscope (Olympus Canada Inc., Richmond Hill, ON) and Spot Basic software (SPOT 
Imaging Solutions, Sterling Heights, MA).  
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Table 2.1  Antibodies used for immunostaining in chapter 2. 
 
 
 Antigen Host Source (catalogue number) Dilution 
1 CD31 Goat polyclonal Santa Cruz (sc-1505) 1:200 
2 vWF Rabbit polyclonal DakoCytomation (A0082) 1:200 
3 VE-cadherin Goat polyclonal Santa Cruz (sc-6458) 1:200 
4 α-SMA Mouse monoclonal Sigma Aldrich (A 2547) 1:200 
5 PDGF-Rβ Mouse monoclonal R&D Systems (MAB1263) 1:200 
6 NG2 Mouse monoclonal Abcam (ab83508) 1:200 
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2.2.3 RNA isolation and qRT-PCR 
 
Using RNeasy Mini Plus or Micro Plus (Qiagen, Mississauga, ON), total RNA 
was extracted from the cells grown in culture. Purity of the RNA samples was 
determined by measuring the absorbance at 260:280 nm in GeneQuant 
Spectrophotometer (Pharmacia Biotech). The quantity was determined by Qubit® Broad 
Range RNA assay in the Qubit® Fluorometer (Life Technologies). cDNA synthesis was 
performed with 200 ng of RNA using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). Primers used for RT-PCR are listed in Table 2.2. RT-PCR reactions 
consisted of 10 µL 2X SYBR Advantage qPCR premix (Clontech Laboratories, Inc., 
Mountain View, CA), 2 µL of both forward and reverse primers (at a 10 µM 
concentration), 2 µL cDNA, and 6 µL of H2O. All reactions were performed for 40 cycles 
using the following temperature profiles: 95°C for 5 minutes (initial denaturation); 55°C 
for 10 seconds (annealing); and 72°C for 12 seconds (extension). 18S rRNA was used 
as the housekeeping gene. PCR specificity was determined by both the melting curve 
analysis and gel electrophoresis, and the data was analyzed by standard curve method. 
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Table 2.2  Primer sequence information for qRT-PCR in chapter 2. 
 
 
Gene Length 
(bp) 
Source (catalogue number) 
 
Adipogenesis markers   
CCAAT/enhancer binding protein alpha 
(C/EBPα) 
88 bp Qiagen (QT00203357) 
Peroxisome proliferator-activated 
receptor γ2 (PPARγ2) 
134 bp 5` → 3` 
ATTGACCCAGAAAGCGATTCC 
CAAAGGAGTGGGAGTGGTCT 
   
Chondrogenesis markers   
NK3 homeobox 2 (Nkx3.2) 100 bp Qiagen (QT01079582) 
Runt-related transcription factor 2 
(Runx2) 
102 bp Qiagen (QT00020517) 
Sex determining region Y-box 9 (Sox9) 111 bp Qiagen (QT00001498) 
   
Endothelial cell markers   
CD31  144 bp Qiagen (QT00081172) 
CD34 106 bp Qiagen (QT00056497) 
Vascular endothelial growth factor 
receptor 2 (VEGFR-2) 
78 bp Qiagen (QT00069818) 
Vascular endothelial cadherin (VE-
cadherin) 
109 bp Qiagen (QT00013244) 
Von Willebrand factor (vWF) 108 bp Qiagen (QT00051975) 
   
Endothelial cell activation markers   
Endothelin 1 (ET-1) 166 bp Qiagen (QT00088235) 
46 
 
Endothelial selectin (E-selectin) 96 bp Qiagen (QT00015358) 
Intercellular adhesion molecule 1 
(ICAM1) 
84 bp Qiagen (QT00074900) 
   
Extracellular matrix (ECM) proteins   
Fibronectin 119 bp Qiagen (QT00038024) 
Collagen 1 118 bp Qiagen (QT00037793) 
Collagen 3 95 bp Qiagen (QT00058233) 
Collagen 4 119 bp Qiagen (QT00005250) 
   
Mesenchymal cell markers   
Alpha smooth muscle actin (α-SMA) 83 bp Qiagen (QT00088102) 
Calponin 78 bp Qiagen (QT00067718) 
Myosin heavy chain (MHC) 130 bp Qiagen (QT00069391) 
NG2 128 bp Qiagen (QT00079884) 
Platelet-derived growth factor receptor β 
(PDGFR-β) 
102 bp Qiagen (QT00082327) 
   
Osteogenesis markers   
Osterix (SP7) 120 bp Qiagen (QT00213514) 
Runt-related transcription factor 2 
(Runx2) 
102 bp Qiagen (QT00020517) 
   
Oxidative stress markers   
Catalase (Cat) 60 bp Qiagen (QT00079674) 
Glutathione peroxidase 1 (GPx) 105 bp Qiagen (QT00203392) 
Heme oxygenase 1 (HO-1) 99 bp Qiagen (QT00092645) 
NADPH oxidase (p22 Phox) 106 bp Qiagen (QT00082481) 
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Inducible NOS (NOS2) 92 bp Qiagen (QT00068740) 
Superoxide dismutase 1 (SOD-1) 150 bp Qiagen (QT01671551) 
   
Housekeeping gene   
18S rRNA 149 bp Qiagen (QT00199367) 
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2.2.4 Cell growth assay 
The growth of the abEPCs and bmMPCs was assayed by plating the cells in 
triplicates on FN-coated multiwell plates at a density of 2500 cells/cm2. The EPCs were 
cultured in complete EBM2/20% FBS media with or without the addition of high glucose 
(25 mmol/L; 450 mg/dL). Cell number was determined on days 1, 6, and 12 using 
Scepter 2.0 Automated Cell Counter (Millipore). The histogram gating was adjusted to 
specifically measure live cells. bmMPCs were also plated at a density of 2500 cells/cm2 
in multiwall plates. However, the cells were cultured in DMEM/10% FBS media with or 
without the addition of 25 mmol/L glucose for 1, 4, and 12 days. The data was 
presented as cell counts. The results were also confirmed by colorimetric assay utilizing 
tetrazolium salt reagent (WST-1, Clontech, Mountain View, CA). Following incubation, 
the absorbance was measured at 450 nm using Multiskan FC Microplate Photometer 
(Thermo Scientific, USA) with 690 nm absorbance as the reference point. 
2.2.5 Caspase-3 activity 
We also tested the effect of high glucose levels on caspase-3 activity (BF3100; 
R&D Systems, Minneapolis, MN) in serum-reduced media (EBM2/1% FBS for 
endothelial cell types and DMEM/1% FBS for mesenchymal cell types). The cells were 
cultured for up to 4 days (longer time periods were not possible as serum reduction 
itself causes cell death) with or without the addition of 25 mmol/L glucose and cell 
lysates were prepared. To measure caspase-3 activity, a caspase-specific peptide 
conjugated to p-nitroaniline was added to the lysates and the cleavage product was 
quantified by measuring absorbance at 405 nm. 
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2.2.6 Cell migration assay 
A migration assay was performed on both abEPCs and bmMPCs using FN-
coated 6.5-mm Transwell inserts with 8.0-μm pores (BD Falcon Cell Culture inserts; BD 
Biosciences, Mississauga, ON). abEPCs were trypsinized and re-suspended in control 
(EBM2/1% FBS) or high glucose (EBM2/1% FBS + 25 mmol/L glucose) media. One 
hundred µL of cell suspension was added to the inserts in triplicates, and at a density of 
10,000 cells/insert. The lower chambers contained 10 ng/mL basic fibroblast growth 
factor (bFGF; 233-FB-025, R&D Systems). The cell density used in this assay was 
optimized for endothelial cells in our pilot studies to provide a robust measure of cell 
migration. Twenty-four hours later, cells on the upper insert were removed and cells in 
the lower chamber that had migrated through the pore were trypsinized. The cell 
suspension was centrifuged, re-suspended in media, and added to 96-well plates in 
order to be measured by the Multiskan FC Microplate Photometer. bmMPC migration 
was measured similarly but with pre-optimized 25,000 cells/cm2. The lower chambers in 
bmMPC migration experiments contained 10% serum as the chemoattractant. 
2.2.7  MPC differentiation assay 
A differentiation assay was conducted on bmMPCs to assess whether they retain 
their multipotential nature under high glucose conditions. Cells were treated with control 
(DMEM/10%) or high glucose media (DMEM/10% + 25 mmol/L) for 7 days before the 
differentiation experiments. To induce differentiation, bmMPCs were seeded at a 
density of 40,000 cells/cm2 on 12-well plates in specific differentiation media (StemPro® 
Adipogenesis/Chondrogenesis/Osteogenesis Differentiation media; Life Technologies). 
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Media was changed every other day. RNA was isolated from cells after 7 and 14 days 
to perform qRT-PCR in order to quantify the differentiation potential. We measured 
peroxisome proliferator activated receptor-γ2 and C/EBPα for adipogenesis, Runx2 and 
osterix (SP7) for osteogenesis, and Sox9, Nkx3.2, and Runx2 for chondrogenesis. 
These transcription factors are essential for the differentiation of multipotential cells into 
the lineages indicated11,12. 
2.2.8 Statistical analysis 
The data were expressed as means ± SEM. Where appropriate, analysis of 
variance (ANOVA) followed by two-tailed student's unpaired t-tests were performed. P 
values <0.05 were considered statistically significant. 
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2.3 Results  
 
2.3.1 Isolation and characterization of abEPCs  
 
Following isolation of the MNC layer from adult blood, cells were cultured in 
complete EBM-2 media supplemented with SingleQuots to induce differentiation into the 
endothelial lineage (abEPCs). Culture of blood-derived cells in high glucose media (HG; 
25 mmol/L) did not significantly alter the number of colonies (figure 2.1). No colonies 
appeared in either control or high glucose level conditions prior to day 14 (data not 
shown; plates were screened daily using phase contrast microscopy). abEPCs were 
then characterized through RT-PCR to confirm expression of endothelial cell-selective 
genes and through immunocytochemistry to properly localize the cellular markers. 
cbEPCs and HDMECs were used as controls. RT-PCR confirmed the expression of 5 
genes of known significance to endothelial cells: CD31, CD34, VEGFR-2, VE-cadherin, 
and vWF (figure 2.2A). The expression of all endothelial-specific genes tested, except 
for VEGFR-2, was significantly higher in abEPCs as compared to mature HDMECs 
(figure 2.2A). Immunostaining showed both CD31 and VE-cadherin localized to the cell 
membrane of abEPCs, as anticipated (figure 2.2B). vWF, an intracellular protein stored 
in Weible Palade bodies, showed intracellular localization. 
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Figure 2.1: EPC and MPC colonies derived from VSCs. abEPCs (n=9) and bmMPCs 
(n=6) were derived from the mononuclear cell layer of adult peripheral blood samples 
and bone marrow samples, respectively.  No significant change in the number of abEPC 
and bmMPC colonies was seen with the addition of HG (25 mmol/L) to the culture 
medium [HG=high glucose]. 
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A 
   
B 
   
 
Figure 2.2: Characterization of human abEPCs. (A) abEPCs were characterized 
through quantitative RT-PCR analysis for expression of known EC-markers: CD31, 
CD34, VE-cadherin, vWF, and VEGFR-2 [mRNA data normalized to 18S rRNA and 
presented relative to HDMECs; *p<0.05 compared to HDMECs; n = 3]. (B) abEPCs 
were further characterized through immunostaining for antibodies against cell surface 
markers CD31 and VE-cadherin, and intracellular marker vWF [Blue: DAPI for nuclear 
staining; Green: Alexa Fluorochrome 488; scale bar represents 100µm] [VE-
cadherin=vascular endothelial-cadherin; vWF=Von Willebrand Factor; VEGFR-
2=vascular endothelial growth factor-2].   
 
 
 
54 
 
2.3.2 Isolation and characterization of MPCs  
 
bmMPC colonies appeared within the first 7 days of culture after isolation of MNC 
from bone marrow. Similar to the abEPC preparations, high levels of glucose did not 
significantly affect the number of colonies derived (figure 2.1). MPCs were then 
subcultured and tested for expression of mesenchymal markers, using uaSMCs as a 
control. bmMPCs expressed mRNA for all mesenchymal markers examined (figure 
2.3A). Interestingly, PDGFR-β was highly expressed in bmMPCs as compared to 
mature uaSMCs (figure 2.3A; p<0.05). Other markers of mesenchymal lineage showed 
significantly lower expression in the bmMPCs. Positive staining was observed for CD90, 
NG2, PDGFR-β, and α-SMA in bmMPCs (figure 2.3B). CD90, NG2, PDGFR-β were 
localized to the cell membrane, whereas α-SMA was intracellular, consistent with actin 
fiber staining. 
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Figure 2.3: Characterization of human MPCs.  (A) qRT-PCR analysis of bmMPCs 
showed expression of mesenchymal markers: calponin, α-SMA, MHC, NG2, and 
PDGFR-β [data normalized to 18S rRNA and presented relative to uaSMCs; *p<0.05 
compared to uaSMCs; n = 3]. (B) MPCs were immunostained for antibodies against 
membrane-bound proteins CD90, NG2, and PDGFR-β, and cytoplasmic protein α-SMA.  
[Blue: DAPI for nuclear staining; Green: Alexa Fluorochrome 488; scale bar represents 
100µm] [α-SMA=alpha-smooth muscle actin; MHC=myosin heavy chain; 
NG2=neuron/glial type 2 antigen; PDGFR-β=platelet-derived growth factor receptor-
beta]. 
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2.3.3 High glucose levels do not alter abEPC growth or migration  
 
To assess the effect of glucose exposure on abEPC growth, we cultured abEPCs 
for a period of 12 days in EBM-2/20% FBS, supplemented with either 5 mmol/L glucose 
(control) or 25 mmol/L glucose (HG). We chose to culture the cells in normal serum 
levels because this setting is reminiscent of the in vivo conditions and would allow us to 
study the effect of chronically elevated glucose levels without the confounding toxicity 
associated with serum-free media. Our results show that the growth of abEPCs, and 
even HDMECs, is not affected by high levels of glucose (figure 2.4A). An increase in 
total cell number was noted at day 6 in the abEPCs. However, this increase was 
normalized (relative to control media containing normal glucose levels) by day 12. 
We then plated a high density of cells and assessed the cell capacity for survival 
in depleted media (1% FBS), and how the addition of high glucose might impede this 
process. Addition of high glucose in 1% serum media reduced the cell number at 24 
hours but had no effect at day 4 (data not shown). To confirm that the reduction in cell 
number was due to apoptosis, we measured caspase-3 activity in the abEPCs and 
HDMECs. Our results show a slight but significant increase in caspase-3 activity in 
abEPCs (1.4x increase as compared to control media without high glucose) (figure 
2.4B). Interestingly, the same conditions led to a 2.3x increase in caspase-3 activity in 
the mature HDMECs (figure 2.4B). As the cells were plated under identical conditions 
(media, cell density, plate coating), these data suggest that abEPCs are more resistant 
to glucose-induced toxicity as compared to the mature HDMECs. 
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Next, we tested whether high glucose causes changes in bFGF-induced 
migration of abEPCs. We treated abEPCs and HDMECs to normal glucose or high 
glucose levels in EBM-2/1% FBS. The cells were seeded on transwell inserts and the 
lower chamber contained 10 ng/mL bFGF. Our results show no significant alteration of 
these cellular processes in both EC types in the presence or absence of high levels of 
glucose (figure 2.4C). 
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Figure 2.4: EPC functional assays. Cells were cultured in control or HG-treated 
media. (A) Growth of abEPCs was assessed as cell viability over a 12 day period in 
high serum media (EBM2/20% FBS). A spike in activity occurred in the hyperglycemic 
group at day 6 (*p<0.05 compared to cells in control media). However, abEPCs showed 
no significant differences between control and HG-treated groups over long-term 
culture. (B) Caspase-3 activity level was measured in abEPCs and HDMECs exposed 
to control or HG media (in EBM-2/1% FBS) for 24 hours [*p<0.05 compared to 
respective control media; †p<0.05 compared to HDMECs in HG media; n = 3]. (C) A 24-
hour migration assay was performed on abEPCs, assessed as their ability to migrate 
through an 8-µm pore with bFGF as the chemoattractant. HG had no effect on the 
migratory abilities of abEPCs, cbEPCs, and HDMECs. 
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2.3.4 HG significantly alters the growth and migration of MPCs 
 
bmMPCs were also subjected to specific cellular activity assays in order to test 
their functional characteristics in a high glucose setting. Similar to the abEPC 
experiments, long-term growth of bmMPCs was measured over the course of 12 days. 
Hyperglycemic bmMPCs showed a significant decrease in cell number on day 1 in the 
presence of high glucose (figure 2.5A). However, with long-term culture in high glucose 
media the growth was seemingly unaffected, as cell number had normalized to control 
cells by day 4. Similarly, no significant changes were observed in serum-depleted media 
(data not shown). We then measured bmMPC migration using a potent mesenchymal 
chemoattractant, FBS. Our results show that cell migration of bmMPCs was reduced by 
nearly 50% in the high glucose group after 24 hours (figure 2.5B).  
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Figure 2.5: MPC functional assays. (A) Growth of bmMPCs was assessed as cell 
viability over a 12 day period in high serum media (DMEM/20% FBS).  HG-bmMPCs 
showed significantly less growth at day 1 as compared to control (*p<0.05 compared to 
cells in control media). However, growth over long-term culture appeared to be 
unaffected by HG. (B) Migration of bmMPCs was assessed in the presence of 10% FBS 
as chemoattractant. Exposure of bmMPCs to HG significantly reduced the migratory 
ability towards FBS (*p<0.05 compared to cells in control media). 
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2.3.5 Effect of glucose on cellular activation, matrix protein expression, and 
redox-sensitive enzymes 
 
We have previously shown altered cellular activity of ECs in high glucose 
conditions and in target organs of diabetic complications13-15. These altered activities 
include changes in the redox enzymes, expansion of extracellular matrix, and 
vasoactive factor alteration. We wanted to determine whether long-term culture of 
vascular progenitor cells would lead to similar alterations. Therefore, we cultured the 
cells in complete media (EBM-2/20% FBS with or without 25 mmol/L glucose) and 
performed a gene expression analyses. We profiled key cell activation genes 
(endothelin-1, ET-1; E-selectin; and intercellular adhesion molecule-1, ICAM-1), matrix 
protein genes (collagens 1,3,4; and fibronectin), and oxidative stress genes (catalase, 
Cat; glutathione peroxidase, GPx; heme oxygenase-1, HO-1; NADPH oxidase, p22 
Phox; inducible nitric oxide synthase, NOS2; and superoxide dismutase-1, SOD-1). 
Interestingly, no significant effect of high levels of glucose was noted in endothelial cell 
activation, oxidative stress parameters, and matrix proteins at day 1, day 3, or day 14 
(figure 2.6). Analysis of bmMPCs also showed no changes in oxidative stress markers 
(figure 2.7A). Significantly increased levels of matrix proteins (collagen 3, collagen 4, 
and fibronectin) in high glucose-treated uaSMCs were seen (figure 2.7B). These same 
matrix protein mRNA levels were significantly reduced in the bmMPCs. 
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Figure 2.6: Gene expression profiles of abEPCs. Cells were cultured in 5 mmol/L 
(control) or 25 mmol/L (high glucose; HG) glucose for up to 14 days in high serum 
media (EBM2/20% FBS). RNA was isolated at day 1, day 3 (data not shown), and day 
14 (data not shown) in order to assess changes in gene expression through qRT-PCR. 
Contrary to what we expected, HG-treated abEPCs, cbEPCs, and HDMECs showed no 
changes in endothelial cell activation genes (A), redox enzymes (B), or matrix protein 
genes (C) [ET-1=endothelin-1; E-selectin=endothelial selectin; ICAM1=intercellular 
adhesion molecule-1; Cat=catalase; GPx=glutathione peroxidase-1; HO-1=heme 
oxygenase-1; p22 Phox=NADPH oxidase; NOS2=inducible NOS; SOD-1=superoxide 
dismutase-1].  
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Figure 2.7: Gene expression profiles of MPCs. Cells were cultured in control (5 
mmol/L) or HG-treated (25 mmol/L) media for up to 14 days. RNA was isolated at day 1, 
day 3 (data not shown), and day 14 (data not shown) in order to assess changes in 
gene expression through qRT-PCR. (A) Oxidative stress marker expression in bmMPCs 
and uaSMCs showed no significant changes upon exposure to high levels of glucose. 
(B) HG induced an increase in the production of matrix proteins in mature uaSMCs, but 
caused downregulation of these same markers in the bmMPCs [*p<0.05 compared to 
control media; n = 3] [Cat=catalase; GPx=glutathione peroxidase-1; HO-1=heme 
oxygenase-1; p22 Phox=NADPH oxidase; NOS2=inducible NOS; SOD-1=superoxide 
dismutase-1]. 
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2.3.6 High glucose enhances adipogenesis of MPCs 
 
We performed mesenchymal differentiation assays on the bmMPCs to assess 
their ability to differentiate into adipocytes, chondocytes, and osteoblasts with the 
addition of high glucose. The cells were pre-treated with high levels of glucose for 7 
days prior to culture in the differentiation media. qRT-PCR was used to examine the 
expression of specific transcription factors involved in the differentiation process 
(adipogenesis was assessed by C/EBPα and PPARγ2; osteogenesis by Runx2 and 
osterix/SP7; chondrogenesis by Sox9, Nkx3.2, and Runx2). The differentiation scheme 
for adipogenesis is outlined in figure 2.8A. High glucose drastically increased the 
differentiation of bmMPCs into adipocytes, as assessed by C/EBPα and PPARγ2 
induction at day 7 (figure 2.8B and 2.8C). At day 14, PPARγ2 levels in cells exposed to 
high glucose were similar to cells in the normal glucose media (figure 2.8D); however, 
C/EBPα levels remained significantly higher (figure 2.8E). 
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Figure 2.8: Differentiation of MPCs into adipocytes. bmMPCs were cultured in 5 
mmol/L (control glucose) or 25 mmol/L (high glucose; HG) glucose for 7 days prior to 
differentiation and assessed for induction of PPARγ2 and C/EBPα (A). HG-treated 
bmMPCs increased adipogenesis at day 7, as demonstrated by upregulated PPARγ2 
levels (B) and C/EBPα (C). Analysis of cells at day 14 showed increased PPARγ2 upon 
differentiation but no differences between control- and HG-treated cells (D). C/EBPα 
levels (E), on the other hand, were significantly higher in HG-treated cells at day 14 as 
compared to control glucose treated cells [*p<0.05 compared to control media; †p<0.05 
compared to cells treated with control glucose + differentiation media] [c/EBP = 
CCAAT/enhancer binding protein; PPARγ2 = peroxisome proliferator-activated receptor 
γ2]. 
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2.3.7 High glucose suppresses differentiation of MPCs to osteoblasts 
 
Next, we assayed for osteogenic differentiation by measuring levels of 
osteogenic transcription factors Runx2 and osterix/SP7 (figure 2.9A). Analysis of cells 
exposed to the differentiation media at day 14 showed that high glucose prevented 
Runx2 induction (figure 2.9B) and significantly reduced osterix/SP7 induction (figure 
2.9C). 
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Figure 2.9: Differentiation of MPCs into osteoblasts. bmMPCs were cultured in 5 
mmol/L (control glucose) or 25 mmol/L (high glucose; HG) glucose for 7 days prior to 
differentiation and assessed for induction of Runx2 and SP7 (A). (B) 14-day 
differentiation of bmMPCs into osteocytes showed significantly depressed expression of 
Runx2 and SP7 in HG treated cells [*p<0.05 compared to control media; †p<0.05 
compared to cells treated with control glucose + differentiation media] [Runx2 = runt-
related transcription factor 2; SP7 = osterix].  
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2.3.8 High glucose suppresses differentiation of MPCs to chondrocytes 
 
Lastly, we determined whether glucose regulates chondrogenesis in bmMPCs. 
Sox9 mRNA levels were found to be elevated in control cells exposed to the 
chondrogenic media at day 7, which was not observed in cells exposed to high levels of 
glucose (data not shown). We then measured these transcription factors at day 14. 
Contrary to what we expected, we found that cells exposed to differentiation media 
alone (i.e. normal glucose levels), significantly downregulated early chondrogenesis 
genes Sox9 and Nkx3.2 (figure 2.10B, C). At this time point, cells exposed to high levels 
of glucose exhibited significantly higher levels of both Sox9 and Nkx3.2 (figure 2.10B, 
C). Recently, it has been shown that unlike the adipogenesis-specific and osteogenesis-
specific transcription factors (determined above), Sox9 plays an essential stage-specific 
role in chondrogenesis11. To test whether high glucose may be delaying these 
differentiation steps, we measured Runx2 (late marker of chondrogenesis) in our assay. 
Our results show that bmMPCs induce Runx2 at day 14, which coincides with repressed 
Sox9 and Nkx3.2 (figure 2.10D). In contrast, cells exposed to high glucose showed 
significantly lower Runx2 levels (figure 2.10D). 
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Figure 2.10: Differentiation of MPCs into chondrocytes. bmMPCs, pretreated with 5 
mmol/L (control glucose) or 25 mmol/L (high glucose; HG) glucose for 7 days, were 
cultured in differentiation media and assessed for induction of chondrogenesis 
transcription factors (A). HG-treated bmMPCs increased expression of Sox9 (B) and 
Nkx3.2 (C) upon culturing in differentiation media. At this point, cells cultured in control 
glucose levels showed repressed levels of both Sox9 and Nkx3.2. [*p<0.05 compared to 
control media; †p<0.05 compared to cells treated with control glucose + differentiation 
media]. (D) Runx2 mRNA levels were induced after 14-day differentiation of bmMPCs. 
Cells treated with HG showed significantly reduced Runx2 expression [*p<0.05 
compared to control media; †p<0.05 compared to cells treated with control glucose + 
differentiation media] [Sox9 = sex determining region Y-box 9; Runx2 = runt-related 
transcription factor 2]. 
70 
 
2.4 Discussion  
 
These studies demonstrate the differential response of vascular progenitor cell 
populations and mature cells to high levels of glucose. The salient findings of our study 
are that: 1) high levels of glucose do not alter derivation of bona fide EPCs and MPCs, 
2) there is no significant cellular dysfunction in the abEPCs, unlike mature ECs, and 3) 
MPCs undergo significant cellular changes in high glucose conditions displaying altered 
differentiation potential. 
It has been well established that high glucose causes many biochemical 
alterations in vascular ECs16, resulting in impaired function13,16,17. These changes are 
evident when ECs are cultured in serum-free media containing high levels of glucose. 
Our studies do show increased caspase-3 activity (molecular correlate of apoptosis) in 
HDMECs exposed to high levels of glucose. Under identical conditions, caspase-3 
activity level was significantly different in abEPCs as compared to HDMECs. 
Furthermore, this toxic effect was found to be acute (evident within 24 hours). Long-
term culture of abEPCs in high levels of glucose did not alter cell activities. It should be 
noted that long-term assessment of cellular activity necessitated the use of serum in the 
media, which may mask the toxic effect of glucose. However, these conditions are 
consistent with early-stage changes in diabetes. Two studies have demonstrated a 
lower circulating number of EPCs (CD34+/VEGFR2+/CD31+) in both type 1 and type 2 
diabetic patients18,19. Further, the number of CD34+/VEGFR2+ cells has been shown to 
correlate with glycemic control, and negatively associate with arterial stiffness in 
diabetic patients20. This may be because of the acute effect of hyperglycemia as the 
EPCs are mobilized from the bone marrow. Although compelling, these recent findings 
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also potentially take into account a reduction in hematopoietic stem/progenitor cells that 
share some of these same surface markers. A recent study has demonstrated impaired 
mobilization of EPCs from the bone marrow in diabetic animals21. They have also 
reported dysfunctional bone marrow stroma to be partly responsible for this alteration21.  
A second group has indicated that the bone marrow microenvironment of type 1 diabetic 
mice can lead to an increase in inflammatory monocytes alongside a decrease in EPCs, 
further exacerbating vascular dysfunctions in these animals22. Taken together, these 
studies point to the bone marrow as a potential junction of hyperglycemia-induced 
damage to stem cells, and may provide an explanation for the decreased number of 
circulating progenitors. An interesting future direction would be to pre-treat abEPCs with 
high glucose in culture prior to administering in diabetic animals to assess whether the 
toxic effects of hyperglycemia are evident in the surviving cells. 
Unexpectedly, we found that the progenitor population most affected by high 
glucose is the mesenchymal cell type. When we cultured bone marrow-derived MPCs in 
high glucose media, we noted a significant reduction in cell numbers at day 1, despite 
normal serum levels. However, this effect was normalized upon continued exposure. 
This is a novel finding, as not much research to date has linked diabetes with changes 
in cells of the mesenchymal lineage. A recent study, however, has indicated that 
advanced glycation end products may be responsible for an increase in reactive oxygen 
species and subsequent decrease in proliferation and migration of bone marrow-derived 
MPCs23.  
MPCs exhibit remarkable plasticity, with the ability to differentiate both in vitro 
and in vivo into a number of mesenchymal phenotypes including those that form bone, 
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cartilage, muscle, fat, and other connective tissues24-26. In addition to affecting bmMPC 
growth and migration, high glucose caused a very prominent change in their 
differentiation potential. MPCs in high glucose exhibited enhanced adipogenesis 
(assessed by PPARγ2 and C/EBPα induction levels) when compared to control cells, 
while their ability to differentiate into alternate lineages (chondrocytes, osteoblasts) was 
impaired. Much research to date has implicated the Wnt/β-catenin signaling pathway as 
a major regulator of this process27,28. Down-regulation of this pathway increases the 
maturation of pre-adipocytes, whereas the use of specific Wnt proteins in vitro has been 
shown to inhibit differentiation to adipocytes29. Whether hyperglycemia directly alters the 
Wnt pathway, leading to skewed differentiation into adipocytes, remains to be 
determined. 
These studies demonstrate the differing response of mature cells and progenitor 
cells to high levels of glucose. We have confirmed that high levels of glucose have a 
toxic effect on mature ECs, inducing significant increases in apoptosis- a notion that has 
been well-established in diabetes research. Conversely, our studies indicate that both 
EPCs and MPCs may be useful therapeutic agents in diabetes. Although the cellular 
activity (growth and migration) of MPCs was disrupted initially, high glucose had little 
effect on both progenitor cell populations over the long-term. Therefore, increasing the 
number of vascular stem/progenitor cells and negating the initial toxic effect of 
hyperglycemia in diabetic patients may prove to be an effective means of restoring 
vascular homeostasis in diabetes. However, before introducing MPCs as a cell therapy 
for diabetic patients, it would be useful to uncover the mechanism behind the skewing in 
differentiation potential that is seen in high glucose. Finding a way to block the 
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conversion of MPCs to adipocytes would be necessary in order to negate the possibility 
that MPCs may differentiate towards this lineage before performing their role in 
repairing vascular dysfunctions.  
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CHAPTER 3 – POTENTIAL MECHANISMS REGULATING ADIPOGENESIS IN 
DIABETES 
 
 In the previous chapter, I investigated the effects of high glucose on endothelial 
and mesenchymal progenitor cell populations. While there is evidence to support a 
therapeutic role for EPCs in diabetes, MPCs demonstrated some dysfunction in a high 
glucose setting. Importantly, the differentiation potential of MPCs was skewed towards 
the adipocyte lineage, while their ability to become both osteoblasts and chondrocytes 
was reduced1.  
In chapter 3, I will focus on the potential mechanism behind this high glucose-
induced alteration, setting the stage for my experimental studies in chapter 4.  
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3.1 MPC lineage commitment  
 
Lineage commitment of MPCs is a tightly controlled process that is governed by 
a variety of endogenous and extracellular signals. Along with changes in the 
cytoarchitecture of the cell, transcription factors, epigenomic modifiers and various 
signaling cascades are activated and de-activated at the appropriate stage for 
successful differentiation to a specified lineage.   
Adipogenesis is divided into two phases known as commitment and terminal 
differentiation. In the commitment phase, MPCs differentiate into preadipocytes – cells 
that no longer have ability to become alternate mesenchymal lineages. Preadipocytes, 
however, will not undergo spontaneous differentiation to mature cells without the 
appropriate exogenous stimuli. A number of factors are responsible for initiating 
commitment of MPCs. Transforming growth factor-beta (TGFβ) superfamily ligands are 
secreted morphogens that are critical for MPC lineage decisions, though their exact role 
in adipogenesis remains unclear. TGFβ expression is positively associated with obesity 
in both human and animal models2, but inhibits adipogenesis of 3T3-F442A cells in vitro 
through Smad signalling3. Paradoxically, Smad3-null mice are resistant to diet-induced 
obesity4, highlighting the discrepancy that is often noted when comparing in vitro and in 
vivo studies of TGFβ and adipogenesis. Other members of the TGFβ superfamily, bone 
morphogenic proteins (BMPs), have been shown to stimulate adipogenesis through the 
activation of both Smads and the p38 kinase pathway5,6. In addition to these signalling 
pathways, studies have shown that the composition and stiffness of the ECM is able to 
influence cell fate decisions. Human MPCs are less likely to differentiate into adipocytes 
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when grown on stiff matrices that have a high concentration of collagen I7,8. ECM 
stiffness regulates tissue tension, which can lead to cell stretching through actin and 
myosin fibre formation. Cell spreading favors osteogenesis, while roundness will 
stimulate adipogenesis9,10. Changes in cell shape are mediated by RHO GTPase-RHO-
associated kinase (ROCK) signalling11. RHO-GDP, the inactive form, is predominant in 
rounded MPCs and promotes adipogenesis, whereas RHO-GTP in stretched cells 
activates ROCK and generates actinomyosin fibre formation11,12.   
In the terminal differentiation phase, preadipocytes will take on all the 
characteristics of fully functional adipocytes. This requires activating hormone 
responsiveness and acquiring the machinery necessary for lipid synthesis and 
transport. The initial phase of adipogenesis is quite poorly characterized, but terminal 
differentiation has been shown to consist of various well-known transcriptional 
cascades. Initially, c/EBPβ and c/EBPδ are transiently expressed for the purpose of 
directly inducing C/EBPα and PPARγ, the two main transcriptional regulators of 
adipogenesis. Not much is known about c/EBPδ regulation, however, c/EBPβ 
expression is increased by cAMP agonists that stimulate the transcriptional activator 
cAMP-responsive element-binding protein (CREB)13,14. While mice lacking either 
c/EBPβ or c/EBPδ protein have only mild developmental defects in adipose tissue15, it 
has been shown that terminal differentiation will not take place in the absence of 
PPARγ16. Two isoforms exist – PPARγ1 and PPARγ2, both of which can stimulate 
adipogenesis. PPARγ2, however, is specific for adipocytes while PPARγ1 is present in 
other MPC-derived cell types17,18. Although an endogenous ligand for this nuclear 
receptor has not yet been reported, studies in 3T3-L1 cells have revealed cAMP 
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agonists as positive regulators of PPARγ. Additional in vitro work has pointed to 
c/EBPs, along with the glucocorticoid receptor, as major regulators of the PPARγ gene 
locus upon adipogenic stimuli19-21. c/EBPα and PPARγ regulate the expression of many 
downstream target genes that are necessary for adipogenesis, as well as feed-back to 
induce their own expression, thus maintaining the mature adipocyte phenotype. To be 
fully functional, terminal differentiation must also consist of the activation of various 
metabolic genes and adipokines, including fatty acid-binding protein 4 (FABP4), glucose 
transporter 4 (GLUT4), leptin and adiponectin.  
Although osteoblasts and adipocytes are derived from the same parent cell, the 
process of osteogenesis is quite varied from its counterpart. TGFβ/BMP signaling is a 
major regulator of bone formation during mammalian development, as well as during 
adult bone repair22,23.  Signal transduction through Smad-dependent (TGFβ/BMP 
ligands, receptors and Smads) and Smad-independent (i.e. p38 mitogen-activated 
protein kinase pathway, MAPK) pathways converge on the master regulator of 
osteogenesis, Runx2. Both adipo- and osteogenesis involve a complex cross-talk 
between various signaling systems including TGFβ/BMP, Wnt, MAPK, Hedgehog, 
Notch, and FGF, though transcriptional regulators, such as PPARγ and Runx2, are 
thought to have the final say in lineage commitment.   
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3.2 Wnt signaling and adipogenesis  
 
Wingless-type MMTV integration site family members (WNTs) are a large family 
of secreted glycoproteins that play a role in cell fate and development. Wnt signaling 
was first described in Drosophila24, and has since been shown to be a highly conserved 
pathway. Wnts are active during embryogenesis, and signal through both autocrine and 
paracrine mechanisms to regulate adult tissue homeostasis as well. There are 19 
known Wnt ligands that bind to transmembrane spanning Frizzled (Fzd) receptors and 
several co-receptors, including lipoprotein receptor-related protein (Lrp)-5/625,26 and 
receptor tyrosine kinase-like orphan receptor (ROR)27,28 . This will initiate signaling in 
either a β-catenin-dependent or –independent manner, also known as canonical and 
noncanonical signaling, respectively. While the cell type and ligand-receptor 
combination is what appears to direct cell signaling, it is generally accepted that 
canonical Wnt ligands include: Wnt2/2b, Wnt3, Wnt7a/b, Wnt8a, Wnt9a/b, and 
Wnt10a/b29. Noncanonical Wnt ligands, then, consist of: Wnt1, Wnt4, Wnt5a/b, Wnt6, 
Wnt11, and Wnt1629. Both pathways are involved in mediating cell proliferation, 
migration, fate, and behaviour and, as such, have been implicated in regulating the 
differentiation of multipotent MPCs to specific lineages.  
The canonical, or β-catenin-dependent, signaling pathway is contingent on β-
catenin stabilization in the cytoplasm30 (figure 3.1). In the absence of Wnt ligands, β-
catenin exists in a degradation complex that consists of Axin, the adenomatous 
polyposis coli (APC) protein, and glycogen synthase kinase 3β (Gsk3β). Enzymatic  
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Figure 3.1: Schematic of canonical Wnt/β-catenin signaling. When the pathway is 
on, a Wnt ligand binds to a Fzd receptor, activating intracellular molecule Disheveled so 
that the destruction complex is inhibited. β-catenin is free to accumulate and can bind to 
a cell surface cadherin or can translocate to the nucleus to stimulate the transcription of 
Wnt target genes. When the pathway is off, the destruction complex member GSK3β 
phosphorylates β-catenin, marking it for ubiquitination and degradation by the 
proteasome [Cad=cadherin; LRP=lipoprotein receptor-related protein].  
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activity by Gsk3β marks β-catenin for ubiquitination, followed by degradation by the 
proteasome31. However, with the binding of Wnt to a receptor complex consisting of a 
Fzd receptor and Lrp co-receptor, Disheveled (Dsh) is activated and enhances the 
phosphorylation of Gsk3β, inhibiting its activity. The degradation complex then 
disassembles and β-catenin is able to accumulate within the intracellular compartment. 
β-catenin can translocate to the nucleus where it interacts with a complex of 
transcription factors, including lymphoid-enhancer-binding factor/T-cell-specific 
transcription factor (LEF/TCF), in order to promote activation of Wnt target genes.  
Non-canonical/β-catenin-independent signaling consists of two pathways 
commonly known as the Wnt/Calcium (Ca2+) pathway (figure 3.2A) and the Wnt/Planar 
Cell Polarity (PCP) pathway (figure 3.2B). Both are much less well characterized than 
the β-catenin-mediated pathway. In the Wnt/Ca2+ cascade, the binding of Wnt proteins 
to a Fzd receptor and Ror1/2 co-receptor activates phospholipase-C (PLC) through the 
action of heterotrimeric G-proteins32. PLC can derive inositol 1,4,5-triphosphate (IP3) 
and 1,2 diacylglycerol (DAG) from the membrane-bound phospholipid phosphatidyl 
inositol 4,5-bisphosphate. IP3 interacts with calcium channels on the membrane of the 
endoplasmic reticulum (ER), resulting in the release of calcium ions. These ions, along 
with calmodulin (which is ubiquitously expressed), activate the Ca2+-sensitive 
calcium/calmodulin-dependent kinase II (CaMKII)33. Ca2+, together with DAG, can also 
stimulate PKC34. Both CaMKII and PKC are responsible for the activation of 
transcription factors, such as cAMP-responsive element-binding protein (CREB) and 
nuclear factor-κB (NFκB).  
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Figure 3.2: Non-canonical/β-catenin independent signaling. (A) The Wnt/PCP 
pathway consists of a Wnt ligand binding to Fzd receptor to activate Dsh. Dsh can 
stimulate RhoA, which binds to its downstream effector ROCK to mediate changes to 
the actin cytoskeleton. Dsh can also stimulate Rac1 which regulates cell survival genes 
through a series of MAP kinases that terminate on JNK. (B) Wnt/Ca2+ mediated 
signaling relies on the activation of PLC through a Wnt ligand-receptor interaction to 
increase the production of IP3 and DAG. IP3 increases intracellular calcium 
concentrations that act in concert with DAG to stimulate PKC, or calmodulin to stimulate 
CaMKII [Cad=cadherin; Dsh=disheveled; RhoA=Ras homolog gene family, member A;  
ROCK=RHO-associated kinase; Rac1=Ras-related C3 botulinum toxin substrate 1; 
JNK=c-Jun N-terminal kinase; Ror=receptor tyrosine kinase-like orphan receptor; 
PLC=phospholipase C; PKC=protein kinase C; CaMKII=calcium/calmodulin-dependent 
kinase II].     
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The PCP pathway was so named for its ability to regulate the polarity of epithelial 
cells within the plane of the epithelium in Drosophila.  Wnt/PCP signaling is initiated by  
specific Wnt ligands binding to Fzd or Ror receptors. Dsh is activated and can directly 
stimulate the small GTPase, Rac1. The Rac1 branch of the PCP pathway regulates cell 
survival through a series of MAP kinases that terminate on c-Jun N-terminal kinase 
(JNK). Upon JNK induction, c-Jun is phosphorylated by the kinase and can form a 
transcriptional complex with AP-1 and c-fos, resulting in the activation of specific cell 
survival genes35. Dsh can also activate RhoA which, in turn, stimulates downstream 
effector ROCK. ROCK is responsible for mediating cytoskeletal changes and plays a 
large role in regulating cell shape and motility.  
Some of the first work implicating a role for Wnt signaling in adipogenesis was 
done by Ross et al. in 2000. They were able to maintain preadipoctyes in an 
undifferentiated state through the use of Wnt10b36. They went on to show that Wnt10b 
exerts its inhibitory actions by blocking the induction of pro-adipogenic transcription 
factors PPARγ and C/EBPα36. To confirm these results, Ross used a dominant negative 
TCF4 which prevented Wnt signaling and caused enhanced differentiation of 
preadipocytes36. Since, many independent groups have indicated a role for Wnt 
signaling in the suppression of adipogenesis. Along with Wnt10b, Wnt136, Wnt3a37, 
Wnt638, and Wnt10a38 have also been deemed negative regulators of this process in 
vitro. Manipulating downstream effectors of the pathway in 3T3-L1 cells appeared to 
mirror these results. The use of a Gsk3β phosphorylation-defective mutant, and a 
pharmacological inhibitor of this same protein, were both shown to block 
adipogenesis39. Additionally, mouse embryonic fibroblasts (MEFs) deficient of the LRP6 
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co-receptor displayed increased adipogenic differentiation40. These findings led to the 
belief that endogenous Wnts act as a switch during adipogenesis; when switched off, 
differentiation of committed preadipoctyes is able to proceed. Studies have confirmed 
that Wnt10b signal is highest in preadipocytes, but diminishes upon subsequent 
differentiation to mature adipocytes36,41. Conversely, levels of Dickkopf-1 (Dkk1) and 
secreted frizzled-related protein-4 (sFRP4), two established inhibitors of canonical Wnt 
signaling, were shown to increase gradually throughout the process of adipogenesis in 
human adipose tissue-derived mesenchymal stem cells42. In vivo studies have allowed 
a more physiological approach to examining the role of canonical Wnt siganling in 
adipogenesis. Transgenic mice overexpressing Wnt10b from the adipocyte-specific fatty 
acid-binding protein-4 (FABP4) promoter have decreased WAT when maintained on a 
regular diet, and are more resistant to diet-induced obesity43. In humans, an inactivating 
mutation in the Wnt10b gene was identified as a proband for early-onset obesity44. 
Interestingly, this mutation was not detected in over 600 healthy control subjects.   
 The reciprocal relationship between adipo- and osteogenesis appears to be 
reflected in the role of canonical Wnt signaling in these two processes. While it is 
thought that β-catenin must be suppressed for differentiation of preadipocytes to 
proceed, it is generally accepted that canonical Wnts promote the maturation of 
osteoblastic precursors into mature osteoblasts45,46. The first indication of this inverse 
association came from the examination of mice expressing Wnt10b from the FABP4 
promoter. Alongside having reduced adipose tissue, these mice were unexpectedly 
found to have increased bone mass39. Mice expressing Wnt10b from the osteocalcin 
promoter in osteoblasts displayed a similar phenotype47, reinforcing the concept of 
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canonical Wnt signaling as a positive regulator of osteoblastogenesis and mineralizing 
activity. Several other canonical Wnt ligands have since been identified as stimulators of 
osteoblast formation in vitro, including Wnt6 and Wnt10a38. Enhancing β-catenin, either 
by the depletion of Wnt antagonists48 or overexpression of specific Wnt ligands47, has 
been shown to induce bone formation in both mice and humans. It appears that Runx2 
is a direct target of beta-catenin/TCF, indicating the mechanism behind these 
phenotypic changes49,50. Further in vivo approaches have demonstrated that osteoblast-
specific deletion of either the β-catenin gene or the APC gene in mice leads to severe 
osteopenia with a concurrent increase in osteoclast number51. This same group 
demonstrated that constitutive activation of β-catenin in the conditional APC-mutant 
mice corrected this increase in osteoclast number and produced greater bone 
deposition51. In a similar study by a different group, stabilization of β-catenin in 
osteoblasts led to an increase in bone mass whereas its deletion resulted in a lower 
bone mineral density52. Taken together, these results indicate a second role for β-
catenin in promoting the inhibition of osteoclast differentiation.    
 The role of non-canonical signaling in MPC lineage commitment has been 
controversial to date. Unlike canonical Wnt10b expression, levels of Wnt5b have been 
shown to increase gradually throughout adipogenesis. Adenoviral overexpression of 
Wnt5b impaired the nuclear translocation of β-catenin, thus antagonizing the canonical 
pathway and enhancing adipogenesis in 3T3-L1 cells53. Other groups have reported 
non-canonical Wnt signaling to be a negative regulator of adipogenesis. Wnt5a 
expression in ST2 cells inhibited this process by directly attenuating PPARγ 
transcriptional activity through the activation of histone methyltransferase SET domain 
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bifurcated 1 (SETDB1)54,55. Non-canonical Wnt signaling has proven to be elusive in 
regards to osteogensis as well. Wnt4 increased bone regeneration of MPCs isolated 
from human craniofacial tissues both in vitro and in vivo56. MPCs cultured in medium 
containing Wnt5a-neutralizing antibodies were unable to undergo osteogenesis, 
indicating a positive role for Wnt5a in this process as well57. More recently, Wnt5a was 
shown to stimulate the osteogenic differentiation of adipose tissue-derived MPCs 
through changes in the actin cytoskeleton controlled by ROCK58. This brings into play 
the concept of mechanical regulation of cell fate decisions. Arnsdorf et al. demonstrated 
that non-canonical Wnt5a signaling causes changes in Ror2 and RhoA, coupled with N-
cadherin mediated β-catenin signaling alterations, to mechanically induce osteogenic 
differentiation59. Taken together, it appears that MPC lineage commitment may be more 
complex than initially anticipated, being regulated by both canonical and non-canonical 
Wnt signaling, as well as the mechanical microenvironment of the cell. 
Although we would like to assign discrete roles for the β-catenin-independent and 
–dependent pathways in MPC lineage commitment and many people have, this is an 
over-simplified approach to a very complex signaling cascade. Examining a single 
canonical or non-canonical Wnt ligand may not be a good representation of these 
signaling systems as a whole. Further, cell lines do not always behave in a similar 
manner to human-derived multi-potent stem/progenitor cells. As such, many 
contradictory results have been published concerning the role of Wnt signaling in MPC 
lineage selection.  In fact, Quarto et al. demonstrated opposing roles for Wnt3a in 
osteogenesis depending on the model system, dosage used, and differentiation state of 
the recipient cell60. This further exemplifies the difficulty of studying Wnt signaling ex 
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vivo and drawing conclusions that convincingly demonstrate a cause and effect 
scenario. For my remaining studies, I will take an all-encompassing approach to 
studying Wnt signaling in adipogenesis in order to elucidate the potential mechanism 
behind the skewing in differentiation potential seen in high glucose. 
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CHAPTER 4 – GLUCOSE ACTIVATES NON-CANONICAL WNT SIGNALING 
LEADING TO ENHANCED ADIPOGENESIS IN MESENCHYMAL PROGENITOR 
CELLS  
 
These studies investigated the role of canonical and non-canonical Wnt signaling 
in MPC differentiation, and how high glucose might modify these pathways. My first aim 
was to establish the alterations in Wnt signaling that occurred at each level of regulation 
with the addition of high glucose. My second aim was to manipulate each pathway using 
both genetic and chemical approaches in an attempt to block the high glucose-induced 
increase in adipogenesis. My final aim was to corroborate these results with in vivo data 
using both rat and human bone marrow specimens. My studies consisted of the 
following:  
 
1. Elucidate the high glucose-induced changes in Wnt signaling during 
adipogenesis. 
2. Establish the precise role of β-catenin in the differentiation of MPCs to    
adipocytes. 
3. Determine the involvement of non-canonical Wnt signaling in the skewing of  
MPC differentiation. 
4. Examine alterations in the bone marrow diabetic stem cell niche. 
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4.1 Introduction  
 
Human bone marrow MPCs are a pool of multipotent cells that give rise to 
adipocytes, osteoblasts, chondrocytes, and perivascular cells. Although direct 
associations between MPC dysfunction and diabetes have been elusive, the 
deregulation of MPC progeny is a likely outcome of the chronic metabolic perturbations 
seen in diabetes. Diabetes has been associated with fatty bone marrow1,2, alongside 
moderate to severe bone loss3-5 and increased fracture risk6,7. Diabetes also induces 
microvascular remodeling in the bone marrow8,9, manifesting as impaired angiogenic 
ability, endothelial cell dysfunction, increased oxidative stress and a reduction in stem 
cell number8. Taken together, it would appear that disruption of the bone marrow 
microenvironment in diabetes might have detrimental consequences on stem/progenitor 
cell function and differentiation.  
We have previously demonstrated that high levels of glucose, similar to levels 
seen in diabetes, cause dysfunction of MPCs10. MPCs showed skewed differentiation 
towards the adipocyte lineage, while their ability to become osteoblasts and 
chondrocytes was impaired. This is the first indication of glucose levels regulating MPC 
fate determination. Not only does this alteration provide an important link between 
diabetes and obesity, but it may also account for the long-term changes that are 
occurring in diabetic marrow. The mechanisms underlying this association, however, 
remain undiscovered. These mechanisms may involve Wnts, a family of secreted 
glycoproteins that play a role in cell fate and development11. In some of the early work 
implicating Wnt signaling in adipogenesis, Ross and colleagues showed that 
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preadipoctyes can be maintained in an undifferentiated state using Wnt10b, which was 
later shown to be mediated by blocking PPARγ and C/EBPα12. These, and other, 
findings led to the notion that Wnt signaling acts as a switch during adipogenesis; when 
switched off, differentiation of committed preadipoctyes is able to proceed. To date 
however, the role of Wnt signaling, canonical or non-canonical (i.e. β-catenin -
dependent and -independent, respectively), in human MPC lineage commitment has 
been controversial. Previous studies have shown that high glucose levels cause Wnt 
activation and nuclear β-catenin accumulation in a number of human cancer cell lines13, 
macrophages14, and mesangial cells15. Therefore, it is crucial to understand how MPC 
differentiation is regulated and to decipher the role of Wnt signaling in this process.   
In this study, we systematically investigate the molecular mechanisms that are 
responsible for the high glucose-mediated alterations in MPC differentiation. We 
hypothesize that high glucose is enhancing adipogenesis through selective modulation 
of Wnt signaling, and that this mechanism is directly responsible for the long-term 
phenotypic changes that are seen in the diabetic bone marrow. 
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4.2 Materials and methods   
 
Experiments were approved by the Research Ethics Board at the University of 
Western Ontario, London, Ontario and the University of Florida, Gainesville, Florida 
(animal experiments).    
 
4.2.1 Isolation and culture of mesenchymal progenitor cells  
 
Fresh bone marrow samples (1M-125, Lonza Inc., Walkersville, MD) were 
obtained and mononuclear cell fraction was prepared as shown by us previously10,16. 
Bone marrow samples were cultured on fibronectin-coated (FN; 1µg/cm2; FC010-10MG, 
Millipore, Temecula, CA) plates in DMEM (Life Technologies, Burlington, ON) media, 
supplemented with 20% FBS (Lonza Inc.), 1X PSF (antibiotic-antimycotic solution; 
Cellgro Mediatech Inc., Manassas, VA), and no additional growth factors. All 
experiments using bmMPCs were conducted on passage 2-6 cells with 3 technical and 
3-5 biological replicates. 
 
To induce differentiation, MPCs were seeded at a density of 40,000 cells/cm2 on 
12-well or 24-well plates (without FN coating) in specific differentiation media 
(StemPro® Adipogenesis; Life Technologies) with recombinant Wnt5a (50 ng/mL; 645-
WN-010, R&D Systems, Minneapolis, MN), Wnt5b (50 ng/mL; 7347-WN-025, R&D 
Systems), and Wnt11 (50 ng/mL; 6179-WN-010, R&D Systems). IWR-1-endo (13659-
10, Cayman Chemical, Ann Arbor, MI) and PNU74654 (3534/10, R&D Systems) were 
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both added at concentrations of 1 μM, 5 μM, and 20 μM. A Wnt signaling agonist 
(Calbiochem CAS 853220-52-7; EMD Millipore) was also used and added at 
concentrations varying from 100 nM to 5 μM. Media was changed every other day.  
RNA was isolated from cells after 7 days in order to perform qRT-PCR. For Oil Red O 
staining, cells were fixed in 10% neutral buffered formalin and placed in 100% 
propylene for 5 minutes before applying 0.5% Oil Red O solution (O0625-25G, Sigma-
Aldrich, Oakville, ON). 
 
4.2.2 RNA isolation and qRT-PCR 
 
Using RNeasy Mini Plus or Micro Plus (Qiagen, Mississauga, ON), total RNA 
was extracted from the cells grown in culture. The quantity was determined by Qubit® 
Broad Range RNA assay in the Qubit® Fluorometer (Life Technologies). cDNA 
synthesis was performed with 200 ng of RNA using iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA). To examine the human Wnt signaling pathway, a 96-well 
RT2 Profiler PCR Array (Qiagen) was used to profile the expression of 84 genes. The 
PCR was performed using RT2 SYBR Green Mastermix. Data was analyzed by CFX 
Manager Software using normalized (ΔCT) method with β-actin normalization. For all 
other mRNA analyses, reactions consisted of 10 µL SsoFast EvaGreen® Supermix 
(Bio-Rad), 2 µL of both forward and reverse primers (at a 10 µM concentration; table 
4.1), 1 µL cDNA, and 6 µL of H2O. All reactions were performed for 40 cycles using the 
following temperature profiles: 95°C for 2 minutes (initial denaturation); and 55°C for 12 
seconds (annealing and extension). Data was analyzed using relative quantity (ΔCT). 
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Table 4.1  Primer sequence information for qRT-PCR in chapter 4. 
 
 
Gene Length 
(bp) 
Source (catalogue number) 
 
Adipogenesis markers   
CCAAT/enhancer binding protein alpha 
(C/EBPα) 
88 bp Qiagen (QT00203357) 
CCAAT/enhancer binding protein beta 
(C/EBPβ) 
121 bp Qiagen (QT00237580) 
CCAAT/enhancer binding protein delta 
(C/EBPδ) 
90 bp Qiagen (QT00219373) 
Peroxisome proliferator-activated 
receptor γ2 (PPARγ2) 
134 bp 5` → 3` 
ATTGACCCAGAAAGCGATTCC 
CAAAGGAGTGGGAGTGGTCT 
   
Stem cell niche factors   
Angiopoietin-1 (Ang1) 111 bp Qiagen (QT00046865) 
Angiopoietin-2 (Ang2) 79 bp Qiagen (QT00100947) 
Nitric oxide synthase 3 (NOS3) 133 bp SA Biosciences (PPH01298E) 
Stromal cell-derived factor (CXCL12) 70 bp Qiagen (QT00087591) 
SDF receptor (CXCR4) 100 bp Qiagen (QT02311841) 
   
β-catenin 130 bp Qiagen (QT00077882) 
Wnt11 88 bp Qiagen (QT00018270) 
   
Housekeeping gene   
β-actin 104 bp Qiagen (QT01680476) 
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4.2.3 Human bone marrow samples 
 
We obtained paraffin and frozen human femoral bone marrow tissue slides of 
both control (US Biomax, Rockville, MD, n=3; age 63 ±2.64 yrs) and type 2 diabetic 
patients (US Biologicals, Salem, MA; US Biomax, and BioChain Institute, Hayward, CA; 
n=4, age 65.33 ± 2.33 yrs/ BMI and duration of diabetes unknown). cDNA samples from 
control and type 2 diabetic patients were obtained from BioChain Institute. Double 
staining was performed using PictureTM Plus Double Staining Kit (Life Technologies).  
Slides were deparaffinized, hydrated through a sequential ethanol gradient and washed 
in PBS.  Slides were then subjected to antigen retrieval in Tris-EDTA buffer (10 mM 
Trizma-base, 1 mM EDTA, 0.05 % Tween-20, pH 9.0) and 120 °C for 120 minutes using 
the Antigen RetrieverTM (2100 Retriever, PickCell Laboratories). Following antigen 
retrieval, endogenous peroxidase activity was quenched with 3% H2O2 diluted in 
methanol for ten minutes. Slides were blocked and primary antibodies (CD133 antibody, 
Abcam ab19898; CD45 antibody, R&D Systems MAB1430) were applied 
simultaneously for one hour. Slides were rinsed in PBS containing 0.05% Tween-20.  
Goat anti-mouse IgG-horseradish peroxidase polymer conjugate and goat anti-rabbit 
IgG-alkaline phosphatase polymer conjugate were then applied for 30 minutes. DAB 
chromogen and Fast Red were used for detection. Slides were counterstained with 
Mayer’s hematoxylin (Sigma-Aldrich) for 30 seconds and mounted using ClearMount™ 
Mounting solution (Life Tehnologies). Images were taken using Olympus BX-51 
microscope (Olympus Canada In., Richmond Hill, ON) equipped with a Spot PursuitTM 
digital camera (SPOT Imaging Solutions, Sterling Heights, MI).  
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 4.2.4 Diabetic animal model 
 
Streptozotocin-induced diabetic rat model was used.  A single intraperitoneal 
injection of freshly prepared streptozotocin (65 mg/kg in citrate buffer, pH 4.5) was 
performed in 8-week old Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN).  
Diabetes was confirmed after one week following streptozotocin injection by measuring 
the blood glucose level (>200 mg/dL; >11 mmol/L) using the FreeStyle glucomonitor.  
Following two months of diabetes, rats were euthanized and femoral bones were 
removed, decalcified, and embedded in paraffin. Tissues were sectioned at 5 µm. All 
animal procedures were in compliance with the National Institutes of Health (NIH) Guide 
for the Care and Use of Laboratory Animals. The protocols for the rat studies were 
approved by the Institutional Animal Care and Use Committee at the University of 
Florida.   
 
4.2.5 Cell transfections  
 
MPCs were grown in culture in EBM2/20% FBS until confluent. On the day of 
transfection, cells were trypsinized, washed, and re-suspended in R buffer (NeonTM 
Transfection System, Life Technologies). Cells were then mixed with control siRNA-A 
(Santa Cruz Biotechnologies, Santa Cruz, CA, sc-37007), β-catenin siRNA (Santa Cruz 
Biotechnologies, sc-29209), GFP-RhoA Expression Vector Set (contains dominant 
negative and wild type; Cell BioLabs, San Diego, CA, STA-452), or GFP-Rac1 
Expression Vector Set (contains dominant negative and wild type; Cell BioLabs, STA-
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450) and subjected to electroporation using Neon Transfection System (Life 
Technologies). Transfected cells were transferred to a 24-well plate containing EBM2 
media without antibiotics. The following day the media was changed to adipogenic 
media (StemPro® Adipogenesis Differentiation media) with or without the addition of 
HG.  
  
4.2.6 PKC activity assay and β-catenin protein levels 
 
MPCs were grown in culture in EMB2/20% FBS until confluent and then 
subjected to various treatments: control (DMEM/10% FBS), HG (DMEM/10% FBS + 25 
mmol/L glucose), Wnt11 (DMEM/10% FBS + 50 ng/mL Wnt11), Adipo (StemPro® 
Adipogenesis Differentiation media), Adipo + IWR (20 μM), and Adipo + PNU (20 μM).  
After 7 days in culture, protein was extracted using Cell Extraction Buffer (Life 
Technologies, FNN0011) with Halt™ Protease and Phosphatase Inhibitor Single-Use 
Cocktail (Thermo Scientific, Waltham, MA) to prevent enzymatic degradation. Total 
protein from each sample was then quantified using Pierce™ BCA Protein Assay Kit 
(Thermo Scientific). Following quantification, total β-catenin (Life Technologies, 
KHO1211) and PKC kinase activity (Enzo Life Sciences, Farmingdale, NY, ADI-EKS-
420A) was measured as per manufacturer’s protocol.  
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4.2.7 Cell staining  
 
Cultured cells were trypsinized and plated (15,000 cells/cm2) on FN-coated 8-
chambered slides one day prior to staining to allow for attachment of cells. 
Immunofluorescence staining of MPCs for β-catenin (1:100, Abcam, ab6302) and 
phospho-PKC T497 (1:75; Abcam, ab59411) was carried out, followed by Alexa488-
conjugated secondary antibody (Life Technologies). Images were taken using Olympus 
BX-51 microscope. β-catenin and p-PKC staining intensity and β-catenin localization 
was quantified by imageJ analysis following background subtraction to account for slide 
to slide variability. 
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Table 4.2  Antibodies used for immunostaining in chapter 4. 
 
 
 Antigen Host Source (catalogue number) Dilution 
1 β-catenin Rabbit polyclonal Abcam (ab6302) 1:100 
2 Ang2 Rabbit polyclonal Abcam (ab153934) 1:75 
3 CD133 Rabbit polyclonal Abcam (ab66141) 1:200 
4 CD45 Rabbit polyclonal Abcam (ab10559) 1:200 
5 p-PKC Rabbit polyclonal Abcam (ab59411) 1:75 
6 Wnt11 Rabbit polyclonal Abcam (ab96730) 1:75 
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4.2.8 Statistical analysis  
 
The data were expressed as means  SEM.  Where appropriate, analysis of 
variance (ANOVA) followed by two-tailed student’s unpaired t-tests were performed.  P 
values < 0.05 were considered statistically significant.   
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4.3 Results  
 
4.3.1 HG primes MPCs to alter their differentiation potential  
 
In our initial studies, we showed that exposure of MPCs to high levels of glucose 
(25 mmol/L; HG) enhances adipogenesis10.  Therefore, we first wanted to assess 
whether the effect of HG on MPC differentiation was transient, or if HG re-programmed 
the cells so that an increase in adipogenesis would still be evident with removal of the 
stimulus.  To do this, we performed a “priming” study as shown in figure 4.1.  We 
compared three experimental groups: 1) cells pre-treated with HG for 7-days prior to the 
adipogenesis assay, 2) cells subjected to the adipogenesis assay in the presence of 
HG, and 3) cells subjected to an adipogenesis assay only.  Degree of adipogenesis, as 
noted by the induction level of adipogenesis-specific transcription factors c/EBP α/β/δ 
and PPARγ2, was similar in groups 2 and 3 (pre-treatment group and adipo + HG 
group), and was significantly higher than group 1 (adipo alone; figure 4.2).  This 
indicates that the effect of HG is not transitory.  Interestingly, PPARγ2 (late marker of 
adipogenesis) levels were significantly lower in the adipo + HG group as compared to 
the pre-treatment group, suggesting that this priming effect may not only be increasing 
adipocyte number, but also accelerating the differentiation process.  
 
 
 
 
 
 
 
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Experimental scheme for priming study. In order to assess the re-
programming ability of HG, three independent experimental groups were compared: 1) 
cells that were pre-treated with HG (25 mmol/L) for 7 days prior to a 7 day adipogenesis 
assay (HG pre-treatment + Adipo), 2) cells that were subjected to a 7 day adipogenesis 
assay in the presence of HG (Adipo + HG), and 3) cells that were subjected to a 7 day 
adipogenesis assay only (Adipo).  
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Figure 4.2: HG primes MPCs to alter their differentiation potential. Following the 
experimental scheme, we examined mRNA levels of adipogenesis-specific transcription 
factors c/EBPα, c/EBPβ, c/EBPδ, and PPARγ2 to measure the extent of differentiation. 
Both HG-treated groups demonstrated a significant increase in adipogenesis as 
compared to control (*p<0.05 as compared to Adipo group). PPARγ2 (late marker of 
adipogenesis) was significantly lower in the Adipo + HG group as compared to the pre-
treated group (†p<0.05), which remained elevated when compared to control (*p<0.05) 
[c/EBP=CCAAT/enhancer binding protein; PPARγ2=peroxisome proliferator-activated 
receptor γ2].  
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4.3.2 HG selectively modulates Wnt signaling during adipogenesis 
 
 
We used a real time PCR-based array approach to profile the Wnt signaling 
pathway during the processes of adipogenesis. Presence of HG in the induction media 
depressed the expression of most Wnt ligands (figure 4.3A). Interestingly, we saw an 
increase in autogenous Wnt11 expression by HG.  Treatment of MPCs with HG alone 
(no differentiation media) also upregulated Wnt11 expression (figure 4.3B), indicating 
that HG, specifically, was responsible for this increase. In contrast to the Wnt ligands, all 
Fzd receptors were upregulated in HG exposure (Figure 4.4A).  Analysis of β-catenin, 
β-catenin inhibitors (TLE1/2 and β-catenin interacting protein-1/CTNNBIP1), and 
downstream target genes demonstrated that HG does not induce β-catenin-mediated 
transcription (figure 4.4B).  When MPCs were treated with HG alone, β-catenin was 
absent from the nucleus, although cytoplasmic and membrane β-catenin protein levels 
showed an increase (figures 4.5A-C). This, again, illustrated that canonical Wnt 
signaling is not transcriptionally active in HG-treated cells. However, the intriguing 
behaviour of Wnt11 transcript levels in HG indicated a potential connection to non-
canonical Wnt signaling.  
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Figure 4.3: HG induces Wnt11. (A) MPCs were differentiated into adipocytes in the 
presence or absence of HG (25 mmol/L) and mRNA expression of Wnt ligands was 
examined. Wnt ligands displayed a varied pattern with the addition of HG to the 
adipogenic induction media. While most were suppressed, there was an upregulation of 
Wnt11. (B) To confirm that HG was responsible for this increase, we profiled the ligands 
in control (DMEM/10% FBS) and HG-treated MPCs, and noted a similar upregulation of 
Wnt11 by HG [HG=high glucose].  
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Figure 4.4: HG selectively modulates Wnt signaling in adipocytes. MPCs were 
differentiated into adipocytes in the presence or absence of HG (25 mmol/L) and mRNA 
expression of specific Wnt signaling genes was examined. (A) Each FZD receptor 
(Fzd1-8) was upregulated in HG-treated adipocytes. (B) Though β-catenin was 
increased in HG, analysis of downstream target genes (CyclinD1/2, Myc, WISP1) and 
negative transcriptional regulators of Wnt signaling (TLE1/2, CTNNBIP1) revealed that 
β-catenin was not active within the nucleus [HG=high glucose; Fzd=frizzled receptor; 
TLE1/2=transducin-like enhancer protein 1/2; CTNNBIP1=β-catenin interacting protein-
1; WIPS1=Wnt1-inducible-signaling pathway protein 1].  
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Figure 4.5: Absence of nuclear β-catenin in MPCs. (A) β-catenin protein localization 
in MPCs after treatment with HG (25 mmol/L) for 24 hours in normal growth media 
(DMEM/10% FBS) [Green = Alexa Fluorochrome 488; β-catenin, blue = DAPI for 
nuclear stain; 20x magnification; insert at 40x; c = cytoplasmic, m = membrane]. 
Quantification of cytoplasmic (B) and membrane (C) β-catenin staining was done using 
ImageJ software (data are represented as mean ± SEM; *p<0.05 compared to control) 
[HG=high glucose]. 
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4.3.3 Wnt11 mediates the effects of HG to stimulate adipogenesis 
 
To determine whether Wnt11 mediates the effects of HG in enhancing 
adipogenesis, we performed MPC differentiation in the presence of exogenous Wnt 
proteins and used Oil Red O staining to highlight resulting lipid droplets. Exogenous 
Wnt5a and Wnt5b, both downregulated by HG (figures 4.3A and B), showed no 
significant effect on adipogenesis (figure 4.6). However, with the addition of non-
canonical Wnt11, the intensity of the Oil red staining was dramatically increased, 
mimicking the effects of HG (figure 4.6).  
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Figure 4.6: Wnt11 enhances adipogenesis. We performed various adipogenesis 
assays with specific modifications to the culture medium and used Oil Red O to stain 
the resulting lipid droplets. MPCs in normal growth media (DMEM/10% FBS; control) 
and those that were subjected to a 7 day adipogenesis assay (Adipo) were used as 
controls. With the addition of HG (25 mmol/L), adipogenesis was enhanced. Wnt5a (50 
ng/mL) and Wnt5b (50 ng/mL) displayed no significant effect. With the addition of Wnt11 
(50 ng/mL), both the intensity and number of cells stained was enhanced, mimicking the 
effects of HG [HG=high glucose].   
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4.3.4 β-catenin positively regulates adipogenesis in MPCs 
 
We further examined the role of Wnt/β-catenin signaling through the use of small 
molecule inhibitors. IWR-1-endo (IWR-1) functions in the intracellular compartment 
where it increases Axin levels, thereby increasing β-catenin degradation (figure 4.7A). 
PNU74654 (PNU), on the other hand, blocks the interaction of β-catenin and TCF/LEF 
(figure 4.7B). To confirm whether these inhibitors are functional, we examined mRNA 
levels of β-catenin and found that β-catenin was highly suppressed with the addition of 
IWR-1 but not in the PNU-treated group (figure 4.7C). We also measured β-catenin 
protein levels and, though results did not reach statistical significance, the pattern was 
reflective of the mRNA results (figure 4.7D). This was expected as IWR-1 only degrades 
“free” β-catenin which is available to participate in the canonical Wnt pathway17. The 
use of IWR-1, which inhibits canonical β-catenin-dependent signaling, showed reduced 
adipogenesis (figure 4.8A,C). On the other hand, PNU treatment showed no change 
(Figure 4.8B). However, mRNA levels of adipogenesis-specific transcription factors after 
PNU treatment revealed inhibition of early C/EBPβ and δ but not the late C/EBPα or 
PPARγ2 (figure 4.8C). This indicates that β-catenin is involved in adipogenesis, but not 
through nuclear accumulation and transcription-dependent mechanisms.   
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Figure 4.7: IWR-1 suppresses β-catenin. Two canonical Wnt pathway antagonists 
were used to assess the role of β-catenin in adipogenesis. (A) IWR-1 works to stabilize 
the destruction complex, thus increasing β-catenin degradation. (B) PNU functions 
within the nucleus to block the binding of β-catenin to the TCF/LEF complex. We looked 
at the effect of IWR-1 and PNU on β-catenin mRNA (C) and protein (D) levels after 7 
days and found that IWR significantly suppresses β-catenin mRNA (data are 
represented as mean ± SEM; *p<0.05 as compared to Adipo) [IWR-1=IWR-1-Endo; 
PNU=PNU74654].   
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Figure 4.8: IWR-1, but not PNU, inhibits adipogenesis. (A) Adding the intracellular 
inhibitor IWR-1 to an adipogenesis assay at increasing concentrations (1 μM, 5 µM, and 
20 μM) caused a dose-dependent decrease in Oil Red O staining after 7 days. IWR-1 
(20 μM) was added alongside HG (25 mmol/L; far right panel) and normalized the 
increase in adipogenesis noted by HG alone (fourth panel). (B) PNU at any 
concentration (1 µM, 5 µM, or 20 μM) had no effect on adipogenesis. (C) Using qRT-
PCR, we found that IWR-1 significantly suppressed adipogenesis-specific transcription 
factors at day 7, while PNU suppressed only c/EBPβ and c/EBPδ (data are represented 
as mean ± SEM; *p<0.05 as compared to Adipo) [IWR-1=IWR-1-Endo; HG=high 
glucose; PNU=PNU74654; c/EBP=CCAAT/enhancer binding protein; 
PPARγ2=peroxisome proliferator-activated receptor γ2].  
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4.3.5 Role of β-catenin in adipogenesis  
 
To confirm the notion that β-catenin is important for adipogenesis, though not 
through transcription-mediated mechanisms, we employed two approaches. First, we 
treated MPCs with a Wnt agonist (a cell-permeable pyrimidine that increases 
intracellular β-catenin levels without altering the destruction complex). We observed 
enhanced adipogenesis after treatment with this agonist (figure 4.9). Then, we used 
small interfering-RNA (siRNA) to knockdown β-catenin. Contrary to what we expected, a 
near complete knockdown of β-catenin dramatically increased adipogenesis (figure 
4.10A, B).  
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Figure 4.9: Wnt agonist enhances adipogenesis. The addition of Wnt agonist to the 
adipogenesis-specific induction media at increasing concentrations (100 nM, 500 nM, 
1M, and 5 M) enhanced Oil Red O staining in a parallel manner, indicating an 
increase in adipogenesis with Wnt agonist treatment.   
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Figure 4.10: β-catenin protein plays a role in adipogenesis. Following transfection of 
MPCs with siRNA (15 μM or 50 μM) to silence the β-catenin gene, we performed a 7 
day adipogenesis assay. (A) mRNA levels of β-catenin indicated a knockdown efficiency 
of greater than 90% when 50 μM siRNA was used. 15 μM β-catenin had no effect (data 
are represented as mean ± SEM; *p<0.05 as compared to control siRNA). (B) qRT-PCR 
analysis of adipogenesis-specific transcription factors revealed that siRNA-induced 
suppression of β-catenin caused a significant increase in adipogenesis (*p<0.05 as 
compared to Adipo + control siRNA) [siRNA=small interfering-RNA; 
c/EBP=CCAAT/enhancer binding protein; PPARγ2=peroxisome proliferator-activated 
receptor γ2]. 
 
 
128 
 
4.3.6 β-catenin depletion induces a switch from canonical to non-canonical Wnt 
signaling  
 
Our previous observations led us to hypothesize that there is a switch from 
canonical to non-canonical Wnt signaling upon β-catenin gene knockdown. Therefore, 
we examined the expression of the likely candidate, non-canonical Wnt11, in MPCs that 
were transfected with β-catenin siRNA and had undergone adipogenesis. We noted 
drastically enhanced Wnt11 levels (figure 4.11) in these cells, pointing to non-canonical 
signaling, and more specifically Wnt11, as the potential mediator of the HG-induced 
increase in adipogenesis.  
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Figure 4.11: Complete β-catenin knockdown activates non-canonical Wnt 
signaling. Wnt11 mRNA was examined in MPCs that were transfected with 15 µM and 
50 µM β-catenin siRNA and had undergone a 7 day adipogenesis assay. Wnt11 mRNA 
levels were drastically elevated in cells treated with 50 µM β-catenin siRNA, indicating 
activation of non-canonical Wnt signaling (data is represented as mean ± SEM; *p<0.05 
as compared to control siRNA) [siRNA=small interfering-RNA]. 
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4.3.7 Adipogenesis is not activated through the Wnt/PCP pathway  
 
Our next objective was to dissect out the non-canonical Wnt pathway and 
determine whether the Wnt/PCP pathway or the Wnt/Ca2+ pathway is involved in 
adipogenesis.  To achieve this, we used genetic and chemical modulation of the key 
players in each segment of the non-canonical pathway. First, we transfected MPCs with 
dominant negative (DN) and wild-type (WT) Rac1.  DN Rac1 enhanced adipogenesis as 
compared to WT transfected cells (figure 4.12A), suggesting that basal Rac1 activity 
may be inhibiting differentiation.  Similar results were obtained when we inhibited Rac1 
using a specific pharmacological Rac1 inhibitor (Z62954982; figure 4.12B).  
Furthermore, RhoA modulation by dominant negative transfection and Rho Kinase 
Inhibitor VII confirmed that both Rac1 and RhoA have overlapping functions in MPCs 
(data not shown).  Rac and Rho are believed to have opposing functions18,19.  This 
suggests that their role during adipogenesis may be related to cell shape change, which 
would result in overlapping readout.   
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Figure 4.12: Adipogenesis is not stimulated through the Wnt/PCP pathway. (A) We 
transfected MPCs with DN and WT Rac1 and performed a 7 day adipogenesis assay. 
DN Rac1 enhanced adipogenesis as compared to WT Rac1 transfected cells (data is 
represented as mean ± SEM; *p<0.05 as compared to Adipo + WT Rac1). (B) We 
confirmed our results using a chemical inhibitor of Rac1. Mirroring the DN results, 
adipogenesis was enhanced after treatment with the Rac1 antagonist, with early 
transcription factors c/EBP and c/EBP being significantly increased as compared to 
control (*p<0.05 as compared to Adipo) [WT=wild-type; DN=dominant negative; 
c/EBP=CCAAT/enhancer binding protein; PPARγ2=peroxisome proliferator-activated 
receptor γ2]. 
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4.3.8 Non-canonical Wnt/Ca2+ signaling stimulates adipogenesis  
 
Building on these studies, we examined the role of the Wnt/Ca2+ pathway in 
adipogenesis.  Inhibition of PKC through Cheletherine chloride (Che) or PCK-ε V1-2 20, 
which specifically blocks the epsilon isoform of PKC, reduced adipogenesis in MPCs 
(figure 4.13A).  To prevent signaling on the alternate side of the same pathway, we 
used KN93 to inhibit CAMKII.  CAMKII paralleled PKC activity during MPC 
differentiation (figure 4.13A).  These results demonstrated a positive role for the 
Wnt/Ca2+ pathway in the regulation of adipogenesis.  Our previous results point to 
Wnt11 as mediating the effects of HG, therefore we tested whether Wnt11 would 
normalize the effects of PKC inhibition.  Interestingly, we found that Wnt11 does 
significantly dampen the effects of both PKC inhibitors (figure 4.13B).  Next, we 
examined phospho-PKC (p-PKC) levels in human MPCs that had been treated with HG 
(25 mmol/L) or Wnt11 (50 ng/mL) for 24 hours in normal media.  We found increased p-
PKC in MPCs treated with Wnt11, but not with HG (figures 4.14A and B).  This may be 
due to the short nature of HG exposure.  Increased p-PKC levels upon Wnt11 treatment 
were found to co-localize to the nucleus (figure 4.14A).  This was an unusual and 
unexpected finding.  Interestingly, PKC-epsilon (PKCε) has been shown to accumulate 
in the nuclei of 3T3-F442A cells20. We confirmed the role of PKC by measuring activity 
and noted the same outcome as with the p-PKC finding (figure 4.14C). Once again, we 
demonstrated a significant increase of PKC activity in the Wnt11-treated group, 
confirming the important relationship between this non-canonical ligand and the PKC-
mediated Wnt/Ca2+ pathway. 
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Figure 4.13: Adipogenesis is activated through non-canonical signaling. (A) To 
examine the Wnt/Ca2+ pathway, we performed a 7 day adipogenesis assay with the 
addition of three chemical inhibitors: Che (general PKC inhibitor), PKC V1-2 (inhibits 
PKCε), and KN93 (inhibits CaMKII). Each of these three inhibitors functioned to block 
adipogenesis (data is represented as mean ± SEM; *p<0.05 as compared to Adipo). (B) 
The presence of Wnt11 (50 ng/mL) in the differentiation media normalized the inhibiting 
function of the PKC blockers (*p<0.05 as compared to Adipo) [Che=cheletherine 
chloride; PKCε V1-2=PKC epsilon inhibitor; c/EBP=CCAAT/enhancer binding protein; 
PPARγ2=peroxisome proliferator-activated receptor γ2].  
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Figure 4.14: Wnt11 stimulates PKC. (A) We carried out immunostaining for p-PKC in 
human MPCs that had been treated with HG (25 mmol/L) or Wnt11 (50 ng/mL) for 24 
hours in normal DMEM/10% FBS media. [Green = Alexa Fluorochrome 488; p-PKC; 
immunostaining at 10x magnification; insert at 40x; red arrow showing specific nuclear 
localization]. (B) We then compared the nuclear staining intensity using ImageJ and 
found a significant increase in the Wnt11 group as compared to control (data is 
represented as mean ± SEM; *p<0.05 compared to control). (C) We also measured 
PKC activity using an ELISA-based assay after treatment with HG or Wnt11 for 24 
hours and showed significantly increased activity by Wnt11 only (*p<0.05 compared to 
control) [p-PKC=phospho-PKC]. 
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4.3.9 Reduced CD133+ stem cells in diabetic bone marrow  
 
In order to investigate whether the enhanced differentiation of MPCs to 
adipocytes is a direct reflection of alterations occurring in the stem cell niche, we 
examined CD133-expressing cell number in human control and type 2 diabetic bone 
marrow samples. Human samples are quite difficult to procure, and we could only 
obtain type 2 diabetic patient samples. However, this afforded us the ability to determine 
stem cell number unambiguously, as CD133 is specific to stem/progenitor cells in 
humans but not rodents. We used immunohistochemistry to stain for CD133+ cells that 
were devoid of CD45 reactivity, as well as CD133+/CD45+ HSCs. The rationale behind 
this was to determine alterations in cells with vasculogenic ability16,21,22.  These subsets 
may comprise MPCs as well as cells that give rise to EPCs, as we have shown 
previously16,21,23,24.  The qualitative analysis demonstrated a lower number of 
CD133+CD45- cells in the diabetic bone marrow (figure 4.15A and B). These findings 
highlight the potential functional consequence of increased bone marrow adiposity.  The 
reduction in CD133-expressing cells may be due to depletion (i.e. MPCs differentiating 
into adipocytes, thereby reducing the number of CD133-expressing cells) or a non-
permissive change in the stem cell microenvironment.   
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Figure 4.15: Vasculogenic stem cells are depleted in diabetic bone marrow. (A) 
Control (n = 3) and type 2 diabetic (n = 4) bone marrow samples were stained for 
vasculogenic stem/progenitor cells (CD133+CD45-) and HSCs (CD133+CD45+). (B) 
Staining was quantified by examining cell count per field, and confirmed a significantly 
lower number of CD133-expressing cells (negative for CD45) in diabetic bone marrow 
as compared to non-diabetic controls (data is represented as mean ± SEM; *p<0.05 
compared to non-diabetic).  
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4.3.10  HG modulates Ang2 in the bone marrow  
    
We looked at various factors that may be responsible for maintaining stem cells 
in a quiescent/undifferentiated state (figure 4.16A), including NO, stromal cell-derived 
factor-1 (SDF-1), Ang1 and Ang225. Although we found no changes in NO, CXCL12 
(SDF-1) or CXCR4 (SDF-1 receptor) (data not shown), we did note the dramatic 
elevation of Ang2 mRNA expression in diabetic bone marrow samples (figure 4.16B). 
Because Ang1 and Ang2 bind to the same Tie2 receptor but antagonize each other’s 
actions26,27, we examined the ratio of Ang1 to Ang2 in our samples and saw a significant 
reduction in diabetic bone marrow (figure 4.16C), indicating a possible role for Ang2 in 
altering homeostasis and disrupting the stem cell niche.  Interestingly, diabetes is 
associated with vascular remodeling in the marrow8 as well as inflammation28, both 
reminiscent of Ang2 actions. Because of the predominant number of adipocytes in the 
marrow samples, we reasoned that adipocytes are the source of Ang2. In support of this 
concept, we induced the differentiation of MPCs into adipocytes in the presence or 
absence of high glucose. As expected, cells treated with HG exhibited significantly 
higher Ang2 levels (figure 4.16D). We also noted an increase in Tie2 mRNA in diabetic 
bone marrow (figure 4.16E), indicating a potential up-regulation of the antagonistic Ang-
Tie signaling system in a high glucose setting.   
   Since type 2 diabetes is associated with increased insulin levels and dyslipidemia 
alongside hyperglycemia, we used a type 1 diabetic rat model to corroborate HG effect 
and Ang2 expression. We obtained femur bone tissues from 2-month-old diabetic and 
control rats (figure 4.17A) and stained for Ang2. A very distinct staining pattern was 
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noted in the diabetic samples, with Ang2 being localized to the marrow adipocytes 
specifically (figure 4.17B). This staining pattern confirms the deregulation of Ang1/2 
upon MPC differentiation, and indicates that the adipocytes themselves are upregulating 
these proteins in response to HG. In addition, diabetic rat tissues displayed more 
positivity for Ang2 than control tissues, highlighting the effect of hyperglycemia. Lastly, 
we stained for Wnt11 to confirm a seminal role for this protein in HG-mediated 
adipogenesis (figure 4.17C). We noted Wnt11 staining in stem/progenitor cells to be 
clustered around the adipocytes. This localization pattern points to a cell autogenous 
role of Wnt11 in initiating differentiation. 
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Figure 4.16: Diabetes modulates Ang2 to initiate disruption of the stem cell niche. 
(A) Factors known to be necessary for maintaining stem/progenitor cells in a 
quiescent/undifferentiated state in the bone marrow stem cell niche. (B) Examining 
mRNA levels of these factors in human control (n = 3) and diabetic (n = 4) bone marrow 
samples revealed a significant elevation of Ang2 in diabetes (data is represented as 
mean ± SEM; *p<0.05 compared to non-diabetic). (C) Ang1:Ang2 ratio in control and 
diabetic samples indicated a substantially lower amount of Ang1 as compared to Ang2 
(*p<0.05). (D) Tie1 and Tie2 mRNA was elevated in human diabetic bone marrow 
(*p<0.05). (E) To confirm the role of Ang2 in adipocytes specifically, we differentiated 
MPCs to the adipocyte lineage in the presence or absence of high glucose and 
examined mRNA levels of Ang2 after 7 days. Again, we noted the significant increase of 
Ang2 in the HG-treated samples (*p<0.05 compared to Adipo) [NO=nitric oxide; 
SDF=stromal cell-derived factor; Ang1/2=angiopoietin-1/2; Tie 1/2=receptor for Ang].  
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Figure 4.17: Localization of Ang2 and Wnt11 in diabetic rat marrow. (A) Phase 
contrast image of femur bone tissue from two month old type 1 diabetic (n = 5) and 
control (n = 6) rats (red arrow highlighting adipocytes). (B) Staining bone marrow for 
Ang2 revealed positivity on the membrane of adipocytes in the diabetic samples only 
[Green = Alexa Fluorochrome 488; Ang2, blue = DAPI for nuclear stain; 20x 
magnification; insert at 40x]. (C) In contrast, immunostaining for Wnt11 revealed 
localization to the stem/progenitor cells surrounding the adipocytes [Green = Alexa 
Fluorochrome 488; Wnt11, blue = DAPI for nuclear stain; 20x magnification; insert at 
40x; red arrow highlighting Wnt11-positive progenitor cells] [Ang2=angiopoietin 2].  
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4.4 Discussion 
 
The present study establishes the molecular mechanisms behind the skewing of 
MPC differentiation potential by high glucose levels and examines, in a broader sense, 
how this may participate in diabetic bone pathology. The salient findings of our study 
include: 1) HG “primes” MPCs, re-programming autocrine Wnt signaling, 2) there is a 
switch from canonical to non-canonical Wnt signaling in adipogenesis, and 3) the non-
canonical Wnt11/PKC pathway is responsible for the skewing of lineage potential that is 
seen in MPCs in high glucose (figure 4.18).   
Much of what we know about the process of adipogenesis comes from studies in 
rodent cell lines (e.g. 3T3-L1 mouse embryo-derived ‘pre-adipocytes’) and rodent 
multipotential cells. The process involves two phases:  the initial commitment phase and 
the later terminal differentiation phase29. Wnt signaling has been linked to the initial 
commitment phase where canonical and non-canonical ligands have been shown to 
regulate adipogenesis-specific transcription factors. Addition of Wnt10b inhibits PPARγ 
and reduces adipogenesis, whereas knockout of LRP6 enhances adipogenesis30,31.  
Interestingly, this signaling pathway tightly regulates osteogenesis as well. Addition of 
Wnt10b has been shown to enhance osteogenesis in rodent bone marrow-derived ST2 
(stromal cell line) cells32. Reports of both positive33 and negative34,35 regulation of 
adipogenesis by non-canonical Wnts are also ample. Early studies indicated a positive 
role for non-canonical Wnts in the regulation of bone mass34,36,37.  
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Figure 4.18: Schematic of seminal findings. HG causes upregulation of autogenous 
Wnt11 in MPCs to increase adipogenesis through the non-canonical Wnt/PKC pathway. 
Adipocytes themselves upregulate Ang2, which may be disrupting the bone marrow 
microenvironment through remodeling or directly causing depletion of CD133-
expressing stem cells.   
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However, a more recent study has convincingly demonstrated enhanced bone 
resorption by non-canonical signaling38.       
We have provided experimental evidence that β-catenin protein is required for 
adipogenesis in human bone marrow-derived MPCs. This role of β-catenin is 
independent of transcription-mediated mechanisms. Interestingly, complete suppression 
of β-catenin induced an unexpected increase in adipogenesis and represented a switch 
from canonical to non-canonical Wnt signaling, evidenced by the dramatic elevation of 
Wnt11. Not only does this demonstrate a dose-dependent effect of β-catenin in vitro, but 
it was the first indication of non-canonical Wnt signaling as being a major player in 
adipogenesis. We also set out to examine the dual non-canonical pathways in order to 
establish a comprehensive understanding of Wnt signaling in the process of 
adipogenesis. While the Wnt/PCP pathway seems to inhibit adipogenesis, the Wnt/PKC 
pathway positively regulated this process. With the use of both a general PKC and 
PKCε-specific inhibitor, we were able to suppress adipogenesis, even in the presence of 
high glucose. Further studies must be done in order to elucidate whether essential 
adipogenic transcription factors PPARγ2 and c/EBPα are a direct target of PKC.  
Since MPCs are an important cellular constituent of bone marrow and give rise to 
the mesenchymal lineage cells including osteoblasts, chondrocytes, and adipocytes, 
chronic hyperglycemia in diabetes may be altering the cellular makeup of the bone 
marrow through disrupting this cell type specifically. Bone loss and increased marrow 
adiposity have become hallmarks of the diabetic bone phenotype1,2, though not much is 
known about the mechanisms behind these changes. Based on our findings, we can 
postulate that hyperglycemia induces Wnt11 in marrow MPCs leading to increased 
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adipogenesis and impaired osteogenesis. Enhanced adipogenesis is associated with 
elevated Ang2 expression. We know that Ang1-Tie2 signaling is involved in the long-
term repopulation of bone marrow HSCs, crucial for the maintenance of the stem cell 
niche39. Elevated Ang2 in diabetes may disrupt Ang1-Tie2 signaling, reducing 
stem/progenitor cells in diabetic bone marrow. Elevated Ang2 may also play a role in 
microvascular remodeling and inflammation in the bone marrow of diabetic patients. 
These observations certainly warrant further studies on the functional significance of 
marrow Ang2 in diabetes. 
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CHAPTER 5 – SUMMARY AND FUTURE DIRECTIONS   
 
5.1 Overall findings and implications   
 
Long-term diabetes manifests in a vast array of secondary complications, and 
throughout my studies I have touched on a number of these. Complications arise due to 
micro- and macro-angiopathies in the target organs. It would then be the most clinically 
relevant to target the vasculature in order to prevent these complications. For this 
reason, my initial studies focused on vascular stem cells – cells that have the capacity 
to differentiate into mature, functional cells of the vascular wall. I investigated the effects 
of HG on derivatives of VSCs- EPCs and MPCs. While I found that late-outgrowth EPCs 
are able to evade the negative effects of HG, MPCs displayed some functional 
impairment. This included skewing of their differentiation potential to the adipocyte 
lineage, the basis of the second portion of my studies. Recently, Wnt signaling has been 
deemed a major regulator of MPC differentiation. Then, to investigate the mechanism 
behind the HG-induced changes in MPCs, I employed a comprehensive approach to 
studying Wnt signaling, examining both the canonical (-catenin dependent) and non-
canonical (-catenin independent) pathways. I have challenged the conventional 
perception of canonical/-catenin-mediated signaling on MPC differentiation. 
Importantly, I have also established the seminal role of Wnt11 in mediating the effects of 
HG by signaling through the Wnt/Ca2+/PKC pathway. Not only is this mechanism 
relevant in regards to MPC fate, but it provides an important link between the HG-effect 
and phenotypic alterations occurring in the diabetic bone marrow.   
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Overall, the implications of these studies are numerous and warrant further 
investigation in order to become clinically feasible. Importantly, we did not report any 
major dysfunctions in our HG-treated EPCs. This progenitor population, then, should 
retain the ability to create vascular networks in vivo, even in the diabetic setting. 
However, blood vessels are composed of two interacting cell types: ECs and 
perivascular cells. Both are necessary for proper functioning of vascular networks and 
maintenance of tissue dynamics. Following our intensive characterization of both EPCs 
and MPCs in a high glucose setting, it appears that MPCs may be responsible for the 
inept vascular repair mechanisms that are noted in long-term diabetes. Their inability to 
migrate and altered differentiation potential indicates that in a situation of 
neovascularization, the supportive role of the perivascular cell is likely missing. Despite 
these alterations, vascular dysfunctions could be corrected by the ex vivo expansion of 
autologous EPCs and MPCs with subsequent implantation of both cell types into the 
site of injury. Direct, versus systemic, injection of the progenitor populations would 
evade problems associated with MPC migration in high glucose. Neovascularization 
using a single cell suspension nestled in a gel scaffold (fibronectin//collagen/matrigel) 
has proven to be successful in the nude mouse model1,2. The presence of red blood 
cells within the lumens of the new vessels indicated that functional anastomoses had 
formed between the implanted cells and host vasculature. The overall impact of creating 
functional and stable vascular networks in vivo would have far-reaching consequences. 
The prospect of cell therapy and tissue engineering would become a much more 
accessible goal; one that is currently unattainable due to our lack of consensus on how 
to immediately perfuse these tissues. Additionally, we would retain the ability to target 
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individual sites of vascular dysfunction, such as in chronic diabetic complications. While 
this field has made many leaps in recent years, additional effort must be focused on the 
preservation of implants and the long-term effects of these types of procedures.  
The notion of MPC dysfunction in diabetes is a novel concept; because of their 
immunomodulatory properties and multi-lineage potential, many groups have focused 
solely on the therapeutic potential of this progenitor cell population. MPCs in diabetic 
animals have been shown to improve wound healing3, cardiac function4, nephropathy5 
and neuropathy6,7. However, these beneficial effects are mostly owing to the paracrine 
role of MPCs, such as their ability to secrete the angiogenic cytokines VEGF and bFGF. 
Although MPCs are certainly useful in various clinical situations, the long-term in vivo 
effects of high glucose on this cell type have been largely overlooked. While we 
previously demonstrated that growth is not altered after 12 days in HG, we also 
indicated their enhanced differentiation to adipocytes. Increased adipogenesis 
correlated with a decrease in both osteogenesis and chondrogenesis, bringing into 
question the possible concurrent regulation of MPC progeny in HG.  
As MPCs are derived from bone marrow, it is not surprising that these 
observations support the typical bone phenotype of diabetic patients. There is hope that 
with the arrest of excessive adipogenesis, there will be a natural correction of the 
various osteogenic dysfunctions that present with chronic diabetes. Many attempts have 
been made to reverse these disorders by targeting the primary transcription factor 
involved in adipogenesis, PPARγ. While there has been some success in this area – as 
well as some evidence to dispute its relevance – in a long-term clinical situation, 
blocking the actions of PPARγ will have negative consequences on lipid metabolism. 
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The gamma isoform of PPAR is found predominantly in adipose tissues and is activated 
by fatty acids or their derivatives to regulate insulin sensitivity. It is therefore not 
surprising that PPARγ is the molecular target for the Thiazolidinedione class of anti-
diabetic drugs. Inhibiting this receptor in diabetic patients, then, may help evade some 
bone disorders, but at the considerable cost of initiating or accelerating severe, insulin-
resistant type 2 diabetes and the metabolic syndrome. Thus, targets upstream to 
PPARγ should be investigated in order to successfully block adipogenesis without 
affecting the lipid metabolism properties of this receptor. We have presented a novel 
mechanism, designating the non-canonical Wnt/Ca2+/PKC pathway as a major regulator 
of adipogenesis. We have also provided evidence that HG enhances adipogenesis by 
activating Wnt11 to initiate this signaling cascade. If we could disrupt the actions of 
Wnt11, this will not only inhibit the HG-induced increase in adipogensis, but may correct 
for associated osteogenic dysfunctions without altering PPARγ. To date, Wnt11 has 
been under-studied. There have been some reports of its involvement in cardiomyocyte 
differentiation8-10, as well as retinoic acid-induced neuronal differentiation11. Others have 
indicated a role for Wnt11 in cancer cell migration12,13. However, no one has studied the 
effects of Wnt11 knockdown on adipocyte differentiation. While it is overly generous to 
conclude that modulation of the Wnt/PKC pathway will solve all diabetic complications, it 
is certainly an avenue of research that is worth exploring. There is hope that with an 
understanding of the complete picture of MPC differentiation, we will one day have the 
capability to tailor it specifically to a patient’s needs.    
At the epicentre of all of my studies lies the VSC. Regarding VSCs, two important 
concepts should be noted. Firstly, this cell type is functionally distinct from the 
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hematopoietic population in the bone marrow. Secondly, VSCs are responsible for 
postnatal vasculogenesis and, as such, differentiate into both EPCs and MPCs. Taken 
together, my studies focus on the bone marrow stem cell niche and suggest the 
premature differentiation of VSCs into adipoctyes in the diabetic condition. An excessive 
increase in adipocytes may modify the microenvironment, further destabilizing 
stem/progenitor cells and causing their activation from a quiescent state. In a slightly 
different scenario, HG is directly altering the niche environment through increased 
adipocyte-derived Ang2. Ang2 itself may play a role in vascular remodeling and 
inflammation. As a result, cellular homeostasis will be disrupted and vasculogenic 
stem/progenitor cells will become severely depleted. MPCs have previously been 
implicated in maintaining the hematopoietic stem cell niche through their structural 
support and elaboration of growth factors14. It seems, then, that there is an intricate 
balance that exists to support this niche, and it is one that may easily tip with the 
disruption of a single constituent. The decrease in VSC number accounts for the bone 
phenotype that is seen with chronic diabetes, and may also explain why vascular repair 
mechanisms are consistently falling short.  
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5.2 Limitations  
 
Although we have successfully revealed several novel findings regarding diabetic 
complications, no study is without limitations. Because we work with human-derived 
stem cells, they must first be isolated from blood/bone marrow and expanded in culture. 
We are limited in our ability to recapitulate the complexity of an in vivo environment, 
meaning that we may be altering characteristics of our isolated cells through chemical 
and physical growth conditions that are necessary for their survival in culture. This 
concept is illustrated in chapter 2, where the outcomes of our EPC functional assays 
were quite varied from many other published results. The likely culprit for these 
differences was our use of 20% fetal bovine serum, when many other groups choose to 
use 1% - indicating how even one component of growth medium can alter a cell’s 
behaviour. The extracellular matrix has been shown to control stem cell fate through 
variations in microenvironment elasticity or stiffness15. Because our MPCs were seeded 
on plastic culture plates, we cannot rule out the possibility that crosstalk between stem 
cells and matrix in vivo may allow for a different outcome when considering 
differentiation in HG. Further studies will require the incorporation of matrix events to 
obtain a clear picture of stem cell properties. It would be interesting to examine whether 
pre-commitment of MPCs to the osteogenic lineage through matrix stiffness could 
partially overcome the effects of HG.  
Another limitation to our studies is the lack of extensive in vivo experimentation. 
Although we included some immunostaining data, it would be beneficial to provide 
evidence of a similar situation (increased marrow adipogenesis and decreased 
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osteogenesis) and mechanism occurring in a human type 1 diabetic marrow sample. 
We would also like to increase our sample size in order to draw stronger conclusions. 
For future manipulation studies of the Wnt/PKC pathway, the streptozotocin-treated type 
1 diabetic mouse would be useful due to its ability to replicate the chronic complications 
of human diabetes. Using this model, we could effectively establish the impact of 
blocking adipogenesis on ostoegenesis, and vice versa. However, we have to keep in 
mind the variation that can present across species and even within a species (i.e. some 
murine MPCs have been shown to differ in terms of behaviour and marker 
expression16,17). Certainly, in vivo studies are a valuable tool for furthering your studies, 
but do not deduct from the importance of utilizing human-derived cells as a model 
system.   
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5.3 Future Directions  
 
In order to efficiently combat the outlined diabetic dysfunctions, it would be most 
beneficial to target the conversion of stem/progenitor cells to adipocytes (figure 5.1). 
Hypothetically, this should resolve alterations occurring in the stem cell niche, 
increasing the number of vasculogenic stem cells available for vascular repair while 
rectifying the osteoporotic disorders associated with chronic diabetes. 
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Figure 5.1: Potential molecular targets for diabetic complications. We would like to 
inhibit the conversion of CD133+ stem cells to adipocytes in an attempt to rectify the 
altered homeostasis in diabetic bone marrow. Potential targets for therapy are 
highlighted: 1) Wnt11 normalization, 2) PKC activity inhibition, and 3) reversal of the 
Ang1/Ang2 ratio.    
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5.3.1 Ang/Tie signaling  
 
The next step in this research project should focus on our intriguing results 
surrounding the Ang-Tie signaling system. We have provided evidence to suggest that 
Ang2 is a direct target of HG, and is up-regulated by marrow adipocytes. This factor 
may be responsible for disrupting cellular homeostasis, causing the differentiation of 
undifferentiated stem cells in the bone marrow niche. Ang2, then, could be a promising 
candidate molecule for effectively blocking this activation.   
 
5.3.2 PKC profiling  
 
The PKC family consists of at least 12 isoforms that differ in terms of expression, 
localization, and functionality18. While we have indicated a potential role for PKCε in 
adipogenesis, it will be important to profile PKC isoforms to establish a clear 
understanding of the Wnt/PKC pathway in this process. In addition, more work must be 
done to determine the downstream targets of PKC. We have shown its nuclear 
localization after Wnt11 treatment, but it would be valuable to uncover its binding 
partners and gene targets.   
 
5.3.3 Targeting Wnt11   
 
We have uncovered a novel and seminal role for Wnt11 in mediating the effects 
of HG on MPC differentiation. We have also demonstrated its dramatic upregulation in 
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the case of decreased -catenin signaling, linking the canonical and non-canonical Wnt 
pathways in this process. We would like to establish whether Wnt11 plays a role in 
adipogenesis in the absence of high glucose, or if its upregulation is a direct effect of 
diabetes. The next step in Wnt11 studies should utilize siRNA/shRNA to block its 
expression. We can then study the effect of knockdown on MPC differentiation to 
adipocytes, as well as attempt to normalize the HG-mediated increase in adipocytes.  
 
5.3.4 Concurrent regulation of adipo/osteogenesis in HG  
  
It would also be valuable to investigate further the effects of HG on osteogenesis. 
Our preliminary results demonstrated the inhibition of canonical Wnt signaling in HG-
treated osteoblasts (data not shown), resulting in a lower number when compared to 
control. We would like to conclusively state whether this was due to an increase in 
adipogenic cues in these cells, or if HG was acting independently to inhibit the process 
of osteogenesis. It would be relevant to study mRNA levels of both adipogenic and 
osteogenic transcription factors in cells that have been differentiated along each lineage 
in the presence of HG. When considering treatment options, these results will have 
various implications (i.e. if regulation proves to be interdependent and we were 
attempting to inhibit HG-mediated adipogenesis, the result could be a drastic, and 
unwanted, osteogenic response). For this reason, it may be more relevant to target 
VSCs directly in order to avoid having to correct for the response of MPC progeny.  
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5.3.5 Crosstalk in the stem cell niche  
 
To further examine alterations that are occurring in the diabetic stem cell niche, it 
would be of interest to replicate the microenvironment in an in vitro setting. To date, the 
consequence of matrix proteins on the outlined process of HG-induced adipogenesis is 
unknown. Discerning the spatial organization of the various cellular components would 
allow us a better understanding of crosstalk mechanisms, and may provide insight into 
new targets for inhibiting the activation of VSCs.      
 
5.3.6 Time-course in diabetic mouse model   
 
Lastly, we would like to test whether our results are mirrored in an in vivo model. 
A time course experiment in diabetic mice over the several months would allow us to 
pinpoint when changes in the bone marrow are taking place, and in which order they 
occur. To establish this novel mechanism of increased adipogenesis (Wnt11/PKC 
signaling) in a rodent model would be an important next step for the eventual translation 
of science to clinical practice.     
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